<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of adrenocortical carcinoma</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of adrenocortical carcinoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of adrenocortical carcinoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">André Lacroix, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gary D Hammer, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lynnette K Nieman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alberto S Pappo, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Martin, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 29, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Adrenocortical carcinomas (ACCs) are rare and frequently aggressive tumors that may be functional (hormone-secreting) and cause Cushing's syndrome and/or virilization, or nonfunctional and present as an abdominal mass or as an incidental finding.</p><p>The management of ACC will be discussed here.<strong> </strong>The clinical presentation and diagnostic evaluation of patients with adrenal masses, the staging workup for ACC, and the management of benign adrenal adenomas are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/137.html" rel="external">"Clinical presentation and evaluation of adrenocortical tumors"</a> and  <a class="medical medical_review" href="/z/d/html/153.html" rel="external">"Evaluation and management of the adrenal incidentaloma"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PRIMARY TREATMENT</span><span class="headingEndMark"> — </span>Our approach to management is largely consistent with the clinical practice guidelines on the management of adrenocortical cancer published by the European Society of Endocrinology in collaboration with the European Network for the Study of Adrenal Tumors (ENSAT) [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Initial surgery</span><span class="headingEndMark"> — </span>Complete surgical resection is the only potentially curative treatment for adrenocortical carcinoma (ACC) [<a href="#rid1">1,2</a>]. For patients with potentially resectable stage I to III disease who are surgical candidates, we recommend complete surgical resection as initial therapy.</p><p>Before proceeding to a surgical excision, all patients must undergo a complete hormonal assessment to determine the secretory activity of the tumor. It is particularly important to identify those with cortisol-producing tumors. These patients, even those with mild hypercortisolism, have some degree of hypothalamic-pituitary-adrenal (HPA) axis suppression and require glucocorticoid coverage to prevent postoperative adrenal insufficiency [<a href="#rid1">1,3</a>]. (See  <a class="medical medical_review" href="/z/d/html/137.html" rel="external">"Clinical presentation and evaluation of adrenocortical tumors", section on 'Hormonal evaluation'</a>.)</p><p>The surgery should be performed in a specialized referral center by teams of surgeons with specific expertise to avoid tumor spillage and incomplete resection, which is associated with a poor prognosis [<a href="#rid1">1,4,5</a>]. (See <a class="local">'Stage and margin status'</a> below.)</p><p>The preoperative preparation for and techniques of surgical adrenalectomy are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/15027.html" rel="external">"Adrenalectomy techniques"</a>.)</p><p>For potentially resectable tumors invading adjacent organs, surgery often needs to be extensive, with en bloc resection of involved organs such as kidney, liver, spleen, pancreas, stomach, and colon [<a href="#rid6">6</a>]. Intracaval extension or tumor thrombus is not a contraindication to surgery; resection may be facilitated by cardiopulmonary bypass [<a href="#rid7">7</a>].</p><p>Suspicious lymph nodes should be resected, but the benefit of routine lymphadenectomy has not yet been established. ACCs often spread via lymphatic drainage. A benefit for routine lymphadenectomy during adrenalectomy was suggested in a report from the German ACC Study Group of 283 patients with completely resected ACC [<a href="#rid8">8</a>]. There was a significantly reduced risk for tumor recurrence and disease-related death (hazard ratio [HR] 0.54, 95% CI 0.29-0.99) in patients who underwent lymphadenectomy versus those who did not. In a second study, peritumoral lymph node resection was associated with improved overall survival (OS) [<a href="#rid9">9</a>].</p><p>Metastatic lymphatic spread may be more extensive than previously thought. In a study of 56 patients with ACC, lymphatic recurrence was detected in a number of areas [<a href="#rid10">10</a>].</p><p>Left-sided ACC (n=36):</p><p class="bulletIndent1"><span class="glyph">●</span>Left renal hilum (50 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Perirenal fat tissue cranial to the renal hilum (47 to 55 percent in ventral and dorsal areas)</p><p class="bulletIndent1"><span class="glyph">●</span>Para-aortic (47 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Interaortocaval (22 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>In the perirenal fat tissue caudal to the renal hilum (17 to 20 percent)</p><p></p><p>Right-sided ACC (n = 20):</p><p class="bulletIndent1"><span class="glyph">●</span>Perirenal fat tissue cranial to the renal hilum (45 to 55 percent in ventral and dorsal areas)</p><p class="bulletIndent1"><span class="glyph">●</span>Interaortocaval (35 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>In the area of the right renal artery (10 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Paracaval (15 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Left para-aortic lymph node (10 percent)</p><p></p><p>Although resection is technically possible for most patients with stage I to III disease  (<a class="graphic graphic_table graphicRef110639" href="/z/d/graphic/110639.html" rel="external">table 1</a>), it is not curative for many, presumably because occult micrometastases are present at the time of initial presentation, even with stage I disease [<a href="#rid11">11-15</a>]. As an example, in a single center report of 202 consecutive cases of ACC, 40 percent of patients with stage I to III disease  (<a class="graphic graphic_table graphicRef110639" href="/z/d/graphic/110639.html" rel="external">table 1</a>) had developed distant metastasis two years after diagnosis (27, 46, and 63 percent of patients with stage I, II, and III disease, respectively) [<a href="#rid16">16</a>].</p><p>However, there is some evidence that outcomes are improving over time. (See <a class="local">'Prognosis'</a> below.)</p><p>Even if the tumor cannot be removed entirely, some clinicians advocate maximal debulking as a means of improving survival [<a href="#rid11">11,17-21</a>], although others disagree as to the survival benefit of this strategy [<a href="#rid22">22,23</a>]. Randomized trials to support routine debulking of nonresectable tumors are lacking, and decision making must be individualized, taking into account the underlying tumor biology, rate of progression, and the histologic grade [<a href="#rid1">1,4</a>]. For patients with advanced functioning tumors, debulking may help to control hormone hypersecretion and increase the efficacy of further therapies [<a href="#rid2">2,5,24</a>]. Overall, however, patients with unresectable disease have a poor prognosis, particularly with high-grade disease, often surviving only three to nine months, and they are often better palliated with medical management [<a href="#rid18">18,25</a>]. (See <a class="local">'Recurrent or advanced adrenocortical cancer'</a> below.)</p><p>The role of neoadjuvant systemic therapy prior to surgery for patients with locally advanced disease is not defined, and this is not considered a standard approach. In adults, one retrospective study suggested that patients with locoregionally advanced tumors with borderline resectable tumors might benefit from cisplatin-based neoadjuvant chemotherapy [<a href="#rid26">26</a>]. However, definitive evidence is still lacking, and therapeutic decisions should be individualized.</p><p class="headingAnchor" id="H4164554"><span class="h3">Laparoscopic versus open resection</span><span class="headingEndMark"> — </span>We suggest open rather than laparoscopic adrenalectomy for patients with ACC. Laparoscopic surgery has largely replaced the open technique for management of benign adrenal pathology, and laparoscopic removal of even large adrenal tumors can be performed safely by experienced surgeons [<a href="#rid27">27-29</a>]. (See  <a class="medical medical_review" href="/z/d/html/15027.html" rel="external">"Adrenalectomy techniques"</a>.)</p><p>However, the role of laparoscopic resection for ACCs is controversial, and open surgery remains the standard approach at least in our centers, despite the European clinical practice guideline on adrenal incidentaloma, which recommends laparoscopic resection for tumors less than 6 cm even when ACC is suspected in the absence of local tumor invasion [<a href="#rid30">30</a>]. Clinical practice guidelines recommend surgery for all tumors with radiologic findings suspicious of malignancy and evidence for local invasion [<a href="#rid1">1</a>]. However, for tumors &lt;6 cm without any evidence of local invasion (unknown if benign or malignant), laparoscopic adrenalectomy is reasonable if the surgeon has sufficient experience. Several retrospective studies have shown more frequent or earlier recurrences and a shorter disease-free survival when this technique is used for management of ACC [<a href="#rid4">4,31-33</a>]. This is not a universal finding, however, and others have shown comparable outcomes from laparoscopic and open adrenalectomy, particularly for tumors up to 10 cm in size in specialized centers [<a href="#rid34">34-38</a>]. Nonetheless, this is not a widely accepted approach, and we and others [<a href="#rid34">34</a>] suggest <strong>open</strong> rather than laparoscopic resection for known or highly suspected ACC, regardless of size [<a href="#rid4">4,31,39,40</a>].</p><p class="headingAnchor" id="H581131945"><span class="h3">Prognostic factors</span></p><p class="headingAnchor" id="H581131967"><span class="h4">Stage and margin status</span><span class="headingEndMark"> — </span>The most important clinical factors that determine prognosis of ACC are disease stage and completeness of resection [<a href="#rid1">1,12,16,17,25,41-45</a>] (see  <a class="medical medical_review" href="/z/d/html/137.html" rel="external">"Clinical presentation and evaluation of adrenocortical tumors", section on 'Staging'</a>). In one observational series of 253 patients from the French Association of Endocrine Surgeons Study Group, five-year OS was 66, 58, 24, and 0 percent for stage I, II, III, and IV (metastatic) disease, respectively [<a href="#rid41">41</a>].</p><p>A modification has been proposed for the ENSAT staging system that incorporates histologic grade of differentiation  (<a class="graphic graphic_table graphicRef86178" href="/z/d/graphic/86178.html" rel="external">table 2</a>) [<a href="#rid46">46</a>]. In one report, incorporating patient age (&gt;55 years) into available staging systems appeared to better predict OS in patients with stage I and II ACC [<a href="#rid47">47</a>].</p><p>However, survival differs widely for any given tumor stage, and many other factors influence outcomes. Regardless of stage, incomplete resection is associated with a poor prognosis (median survival generally less than one year) [<a href="#rid4">4,5</a>]. The influence of margin status on prognosis was shown in a report from the National Cancer Database, in which five-year OS rates for patients with ACC and uninvolved, microscopically involved, and macroscopically involved margins were 46, 21, and 10 percent, respectively [<a href="#rid48">48</a>].</p><p class="headingAnchor" id="H581132236"><span class="h4">Histology</span><span class="headingEndMark"> — </span>In addition to stage and completeness of resection, the biologic behavior of ACCs is also influenced by pathologic/morphologic factors. Histologically, the appearance of ACCs ranges from mild atypia to wildly anaplastic tumors composed of monstrous giant cells. The widely applied multifactorial scoring system of Weiss is based upon nine histopathologic features (nuclear grade, mitotic rate, atypical mitoses, clear cell component, diffuse architecture, tumor necrosis, invasion of venous or sinus structures, or tumor capsule); tumors with less than three features are usually considered as benign [<a href="#rid49">49</a>]. (See  <a class="medical medical_review" href="/z/d/html/137.html" rel="external">"Clinical presentation and evaluation of adrenocortical tumors", section on 'Fine-needle aspiration biopsy'</a>.)</p><p>These criteria have been validated as prognostic factors in more contemporary series both in adults and children [<a href="#rid12">12,43,44</a>]. As an example, in one study of 124 patients with ACC, significant predictors of disease progression included distant metastasis at presentation; tumor invasion of vessels, tumor capsule, or adjacent organs; tumor necrosis; a high mitotic rate; the presence of atypical mitosis; and overexpression of mdm-2 [<a href="#rid12">12</a>]. Five-year disease-free survival was significantly different for patients with one or two, three or four, or more than four adverse features (84, 37, and 9 percent, respectively).</p><p>Several studies confirm the prognostic value of markers of proliferation, including mitotic rate, and Ki-67 expression (as detected by a monoclonal antibody against Ki-67, MIB-1) [<a href="#rid12">12,50-54</a>]. The importance of proliferative rate in prognostication was shown in an analysis of 124 patients with ACC, in whom the five-year disease-specific survival rates for individuals with tumor mitotic rates of ≤5, 6 to 10, 21 to 50, and &gt;50 per 50 high-power fields [HPF] were 63, 50, 25, and 0 percent, respectively [<a href="#rid12">12</a>].</p><p>The combined utility of tumor stage and mitotic rate to assess prognosis was addressed in a study of 92 patients with malignant ACC [<a href="#rid51">51</a>]. Three risk groups were identified (low [stage I/II, mitoses ≤9/50 HPF], intermediate [stage I/II plus &gt;9 mitoses/50 HPF or stage III/IV plus mitotic rate ≤9/50 HPF], and high [stage III/IV and mitotic rate &gt;9/50 HPF]) that had significantly different rates of mean disease-free survival (62, 17, and 12 months, respectively) and OS (not attained, 66, and 26 months, respectively).</p><p>The Ki-67 labeling index (LI) has been used to select patients for adjuvant chemotherapy in addition to <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a>. While the absolute value of Ki-67 LI that permits the differentiation of a very high-risk ACC from low- or intermediate-risk ACC is not established [<a href="#rid3">3,55</a>], a high-grade ACC, which is defined in part by a high mitotic rate (and/or Ki-67 score ≥20 percent), is at a higher risk of recurrence than a low-grade ACC. (See <a class="local">'Patients with very high recurrence risk'</a> below.)</p><p class="headingAnchor" id="H581132854"><span class="h4">Other factors</span><span class="headingEndMark"> — </span>Other clinical factors, immunohistochemistry, and molecular markers are associated with poor survival. Among clinical factors, older age at diagnosis and hypersecretion of cortisol have been recognized as adverse factors [<a href="#rid16">16</a>].</p><p>Molecular predictors of malignant potential and survival are emerging, but none are ready for clinical use [<a href="#rid56">56-61</a>].</p><p>Some reports suggest the value of mutated <em>TP53</em>, mutated b-catenin<em>,</em> <em>ERCC1</em> (excision-repair, complementing defective in Chinese Hamster 1 gene), <em>IGF2,</em> <em>SF1</em> (splicing factor-1), the glucose transporter <em>GLUT1</em>, low expression of the <em>SGK1 </em>(serum/glucocorticoid-regulated kinase 1) gene, and <em>G0S2 </em>(G0/G1 Switch 2 gene) hypermethylation are predictors of poor prognosis [<a href="#rid12">12,62-69</a>]. Studies with global gene expression profiling suggest that specific patterns of gene expression are strongly associated with poor outcomes, independently of traditional histologic predictors such as tumor stage and Weiss score [<a href="#rid56">56,57,59,61,70</a>].</p><p class="headingAnchor" id="H2563898231"><span class="h1">TREATMENT AFTER INITIAL SURGERY</span></p><p class="headingAnchor" id="H2304262931"><span class="h2">Approach to adjuvant therapy</span><span class="headingEndMark"> — </span>For patients with resected adrenocortical carcinoma, the decision to offer adjuvant therapy is primarily based upon the risk of disease recurrence, which is influenced by three major prognostic factors: tumor stage, completeness of resection, and proliferation rate (as determined by the mitotic rate, MIB-1 staining, or Ki-67 expression) [<a href="#rid49">49,51,52,55,71</a>]. (See <a class="local">'Prognostic factors'</a> above.)</p><p>Patients at lower risk of recurrence typically have a good prognosis and may be candidates for surveillance. In contrast, those at higher recurrence risk may be candidates for adjuvant therapy, such as systemic therapy containing <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> or radiation therapy. The use of molecular markers to better define individual risk for recurrence and tailor decisions about therapy remains investigational [<a href="#rid56">56,61</a>]. (See <a class="local">'Other factors'</a> above.)</p><p class="headingAnchor" id="H3540448434"><span class="h3">Patients with low recurrence risk</span><span class="headingEndMark"> — </span>For most patients at low risk of recurrence after complete resection (stage I to III disease, microscopically complete [R0] resection, Ki-67 ≤10 percent), we suggest observation rather than adjuvant <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a>. In a randomized clinical trial, the use of adjuvant mitotane did not significantly improve recurrence-free survival (RFS) or overall survival (OS) over observation in this low-risk population [<a href="#rid72">72</a>]. These recommendations are consistent with guidelines from the European Society of Endocrinology/European Network for the Study of Adrenal Tumours (ENSAT) and endorsed by A5 (American Australian Asian Adrenal Alliance) as outlined by an international consensus panel on the treatment of ACC [<a href="#rid52">52</a>].</p><p>Alternatively, adjuvant <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> may be appropriate for select patients who meet criteria for low-risk disease but also harbor some features that suggest a potential risk for recurrence. Examples include patients with stage III low-grade disease, or those with a large (&gt;20 cm) stage II tumor with a borderline mitotic rate or Ki-67 score. However, if such patients are treated, a shorter duration would be appropriate (eg, two years), with low threshold to discontinue mitotane if side effects are difficult to manage. Further details on the optimal duration of adjuvant mitotane are discussed below. (See <a class="local">'Duration'</a> below.)</p><p>The approach to adjuvant therapy in patients with low-risk, resected ACC disease is evolving as survival rates have improved over time [<a href="#rid73">73</a>]. Although initial observational data supported the use of adjuvant therapy after resection in most patients with ACC due to high recurrence rates [<a href="#rid12">12,74,75</a>], subsequent studies have suggested that patients with low-risk disease have favorable five-year RFS rates of approximately 75 percent [<a href="#rid72">72,73</a>]. Further data on the efficacy of adjuvant therapy in resected ACC are discussed below. (See <a class="local">'Efficacy'</a> below.)</p><p>These observational studies led to a randomized clinical trial (ADIUVO) in 91 patients at low-risk for ACC [<a href="#rid72">72</a>]. Low-risk features included stage I to III ACC, completed (R0) resection, and Ki-67 ≤10 percent. In this study, patients were randomly assigned to either a minimum of two years of adjuvant <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> or observation. For patients receiving mitotane, the median duration of therapy was 21 months. Adjuvant mitotane, when compared with observation, failed to demonstrate statistically significant improvements in RFS at median follow-up of 48 months (five-year RFS 79 versus 75 percent, HR 0.74, 95% CI 0.3-1.85) or OS at median follow-up of 55 months (five-year OS 95 versus 86 percent, HR 0.46, 95% CI 0.08-1.92). A concurrent observational (ADIUVO OBSERVATIONAL) study demonstrated similar results, with a recurrence rate of 21 percent among patients with low-risk disease. The trial was closed early due to low accrual rates; additionally, despite recruitment at centers of excellence, few patients met the inclusion criteria for mitotic rate (Ki-67 ≤10 percent).</p><p>Data from the German ACC registry suggest that observation alone is also appropriate if patients also have a tumor size &lt;8 cm and no microscopic evidence of invasion of blood vessels or the tumor capsule, in addition to the criteria for low-risk disease [<a href="#rid76">76</a>].</p><p class="headingAnchor" id="H1049041865"><span class="h3">Patients with high recurrence risk</span><span class="headingEndMark"> — </span>For patients at high risk of recurrence, we suggest the use of adjuvant <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> use alone (without chemotherapy) rather than observation alone. Clinical features that indicate high recurrence risk include any one of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Histologically high-grade disease (Ki-67 staining of &gt;10 percent and &lt;20 percent of tumor cells [<a href="#rid77">77</a>] or &gt;20 mitotic figures per 50 HPF regardless of tumor size [<a href="#rid46">46,78</a>]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Incompletely resected disease [<a href="#rid52">52</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intraoperative tumor spillage from tumor fracture or capsule rupture.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Large, low-grade tumors with vascular or capsular invasion.</p><p></p><p>This approach is consistent with clinical guidelines from the European Society of Endocrinology as outlined by ENSAT and endorsed by A5 in international consensus panel guidelines [<a href="#rid52">52</a>]. Further details on the efficacy, toxicity, and administration of adjuvant <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> are discussed below. (See <a class="local">'Adjuvant mitotane'</a> below.)</p><p class="headingAnchor" id="H3055021874"><span class="h3">Patients with very high recurrence risk</span><span class="headingEndMark"> — </span>Although high-quality data are limited, patients at very high risk for an early recurrence (eg, very high Ki-67 staining [≥20 percent]) and extensive vascular invasion/vena cava thrombus) may be offered an adjuvant regimen that includes the addition of cisplatin-based chemotherapy to <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a>. However, it is not known if cytotoxic chemotherapy alone or in combination with mitotane is more effective than adjuvant mitotane alone [<a href="#rid3">3</a>].</p><p>Data on the efficacy of cytotoxic chemotherapy in the adjuvant setting are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective cohort study, 31 patients aged 4 to 59 years with resected ACC and very high risk disease (median Ki-67 of 30 percent) received adjuvant platinum-based chemotherapy [<a href="#rid79">79</a>]. Most patients received a combination of either <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> or <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> plus <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> and a majority (28 patients) were also treated with adjuvant <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a>. Compared with matched controls, the addition of adjuvant platinum-based chemotherapy to mitotane was associated with improved RFS (HR 0.19) and OS (HR 0.26) three months after surgery.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a separate case series, the combination of <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> and <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> was explored in the adjuvant setting among five individuals aged 1.2 to 21 years [<a href="#rid80">80</a>]. All received etoposide 165 mg/m<sup>2</sup> and cisplatin 90 mg/m<sup>2</sup> every three to four weeks for at least six cycles, beginning shortly after surgical resection, and all remained in remission 29 to 109 months later. However, ACC in children has a different natural history than that arising in adults. (See <a class="local">'Pediatric patients'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other adjuvant therapies have been evaluated, such as the combination of <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> plus streptozotocin [<a href="#rid81">81</a>], but these approaches remain investigational.</p><p></p><p>The use of Ki-67 LI to select patients for adjuvant chemotherapy in addition to <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> has been suggested [<a href="#rid71">71,76</a>]. A potential prognostic role for Ki-67 LI following complete resection of ACC was shown in an analysis of 319 patients with resected ENSAT stage I to III ACC [<a href="#rid55">55</a>]. On multivariate analysis, age, tumor size, venous tumor thrombus, and Ki-67 LI were all significantly correlated with RFS and OS; however, Ki-67 LI was the most important prognostic factor. The median RFS durations in patients with a Ki-67 LI &lt;10, 10 to 19, and ≥20 percent were 53, 32, and 9 months, respectively; the corresponding values for median OS were 181, 114, and 42 months, respectively. Importantly, the predictive value of Ki-67 LI (ie, its ability to predict benefit from cytotoxic chemotherapy) was not addressed.</p><p>While the absolute value of Ki-67 LI that permits the differentiation of a "high-risk" from low- or intermediate-risk ACC is not established [<a href="#rid3">3</a>], a high-grade ACC, which is defined in part by a high mitotic rate (and/or Ki-67 score ≥20 percent), is at a higher risk of recurrence than low-grade ACC.</p><p class="headingAnchor" id="H4"><span class="h2">Adjuvant mitotane</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">Mitotane</a> (o,p'-DDD, a congener of the pesticide dichlorodiphenyltrichloroethane [DDT]) is an adrenocorticolytic drug that has efficacy in patients with ACC [<a href="#rid11">11,82-84</a>]. It has been used in the adjuvant setting for primary therapy of unresectable disease and for the treatment of disease recurrence, either alone or in combination with other cytotoxic agents. (See <a class="local">'Mitotane monotherapy'</a> below and  <a class="medical medical_review" href="/z/d/html/119.html" rel="external">"Medical therapy of hypercortisolism (Cushing's syndrome)", section on 'Mitotane'</a>.)</p><p class="headingAnchor" id="H6353019"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>Data demonstrating the benefit of routine postoperative (adjuvant) administration of <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> have been mixed, in large part due to the rarity of ACC and the lack of prospective, randomized clinical trials. While a number of uncontrolled reports suggest that adjuvant mitotane may delay or prevent recurrence in patients undergoing complete primary resection for nonmetastatic disease [<a href="#rid4">4,14,73,75,85-91</a>], others have failed to show any benefit in terms of disease-free or OS [<a href="#rid5">5,17,23,41,50,74,92-97</a>]. Among the potential reasons for these disparate results are insufficient dosing in some studies and variability in an individual tumor's ability to metabolize mitotane (which is required for therapeutic action).</p><p>The best available evidence that adjuvant <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> improves outcomes for patients with resected stage I to III ACC comes from a retrospective analysis of 177 patients who had undergone macroscopically complete radical surgery at eight Italian and 47 German centers between 1985 and 2005 [<a href="#rid75">75</a>]. In the Italian cohort, 47 received adjuvant mitotane while 55 patients did not (Italian control group). None of the 75 patients in the German cohort received adjuvant mitotane (German control group).</p><p>The groups were well matched, with the exception that the German control patients were more likely to have stage I or II disease (84 versus 67 percent of both Italian groups). With a median follow-up that ranged from 43 to 68 months in the three groups, the following results were seen:</p><p class="bulletIndent1"><span class="glyph">●</span>In the <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> group, 27 patients received 1 to 3 grams daily, and the remainder received 3 to 5 grams daily. Serum levels were not routinely measured. The median duration of treatment was 29 months for both doses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">Mitotane</a> treatment was associated with a significantly longer RFS as compared with either control group (median RFS 42 versus 10 and 25 months in the Italian and German control groups, respectively).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There were also fewer deaths from ACC in the <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> group than in either control group (25 versus 55 and 41 percent, respectively). Median OS durations in the three groups were 110 months in the mitotane group compared with 52 months in the Italian controls and 67 months in the German control group.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">Mitotane</a> was reasonably well-tolerated. Grade 3 gastrointestinal (nausea, vomiting, or elevated serum gamma-glutamyl transpeptidase [GGT]) or neurologic events (confusion, ataxia, vertigo) were observed in 15 and 20 percent of the patients who received the higher dose mitotane regimen; neither of these problems occurred with lower doses.</p><p></p><p>These data support the view that adjuvant <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> therapy, even at relatively low doses, improves RFS and OS after macroscopically complete radical resection for stage I, II, or III ACC. The strengths of this retrospective series include its large size, involvement of multiple institutions, well-matched control cohort, long duration, systematic nature of follow-up, and carefully conducted statistical analysis [<a href="#rid91">91</a>]. A report of this cohort after nine additional years of follow-up suggests that the benefit of adjuvant mitotane on disease-free survival is maintained [<a href="#rid98">98</a>].</p><p>Benefit was also supported by three other studies [<a href="#rid73">73,99,100</a>]. In one report of 149 German ACC registry patients with stage II ACC, the subgroup of 35 patients who received adjuvant <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> displayed a significantly better five-year survival than the 114 patients not receiving adjuvant mitotane (87 versus 53 percent, respectively). In a retrospective study of 100 patients treated with adjuvant mitotane and 52 who did not receive mitotane, adjuvant therapy lowered the risk of recurrence but did not improve OS [<a href="#rid100">100</a>]. However, a survival benefit was seen in a subset of mitotane-treated patients (those with stage III ACC or an elevated Ki-67 index).</p><p class="headingAnchor" id="H957045"><span class="h3">Duration</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High-risk ACC</strong> – For patients with resected high-risk ACC, independent of stage, we aim to continue adjuvant <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> for three to five years, depending on tolerability and the length of time patient has achieved target therapeutic mitotane levels. The rationale for this duration is that it is very atypical for a patient with ACC to recur after four to five years. (See <a class="local">'Patients with high recurrence risk'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low-risk ACC</strong> – Observation is preferred for most patients with resected low-risk ACC. However, for those with indications for adjuvant therapy, we aim for a minimum of two years of adjuvant <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> [<a href="#rid1">1,71</a>], based on the duration of administration used in the ADIUVO trial [<a href="#rid72">72</a>]. For patients with low-risk disease and tumor spillage, we will, at times, continue adjuvant therapy for up to five years if the drug is well tolerated [<a href="#rid4">4</a>]. In various studies, the median duration of adjuvant mitotane ranges between 21 and 29 months [<a href="#rid72">72,75</a>]. (See <a class="local">'Efficacy'</a> above and <a class="local">'Patients with low recurrence risk'</a> above.)</p><p></p><p class="headingAnchor" id="H7"><span class="h3">Suggested regimen</span><span class="headingEndMark"> — </span>While benefit of <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> in the adjuvant setting has been reported using relatively low doses (1 to 3 grams daily) [<a href="#rid75">75</a>], current treatment protocols are based upon achieving therapeutic mitotane serum levels. We suggest that all patients receiving mitotane (including those being treated for advanced disease) undergo therapeutic monitoring with plasma mitotane levels every four to six weeks.</p><p>The following represents our approach to managing therapy with <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a>:</p><p class="bulletIndent1"><span class="glyph">●</span>We initiate adjuvant treatment as soon as possible after surgery (within three months).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">Mitotane</a> is initiated at 0.5 g twice per day and increased to 6 g/day over 4 to 12 weeks as tolerated, with monitoring of mitotane level every two to three weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Because of the long serum half-life and accumulation in adipose tissue, several weeks may be necessary to raise serum <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> concentrations to the target level of 14 to 20 mcg/mL [<a href="#rid96">96,101</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When serum <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> monitoring is not available, we suggest trying to push dosing to toxicity (up to 6 to 8 g per day) for patients with high-risk disease and adjust according to tolerability. Some patients may not tolerate more than 2 g per day.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At some centers, <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> is administered to all patients using rapid escalation of high doses (4 g/day rapidly escalating to therapeutic doses within two weeks) [<a href="#rid102">102</a>]. This regimen may shorten the time needed to reach therapeutic levels of mitotane, but it requires closer follow-up and combined clinical and mitotane level monitoring and may be more frequently associated with side effects.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nausea should be treated using <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">metoclopramide</a> or a serotonin (5-HT3) receptor antagonist such as <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">ondansetron</a>. (See  <a class="medical medical_review" href="/z/d/html/1151.html" rel="external">"Prevention of chemotherapy-induced nausea and vomiting in adults"</a>.)</p><p></p><p>Our approach of measuring serum <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> levels, targeting a range of 14 to 20 mcg/mL, has been validated in several studies as correlating with therapeutic response while minimizing toxicity [<a href="#rid6">6,93,96,101,103-106</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective series included 91 patients receiving <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> for unresectable or metastatic ACC who underwent assay of serum mitotane levels within three months of attaining the best response to mitotane with or without chemotherapy [<a href="#rid104">104</a>]. A significantly higher number of responders (11 of 17 responders) had serum mitotane levels &gt;14 mcg/mL, and of the six responders who had lower levels, all were receiving concurrent chemotherapy. Survival was also significantly longer among patients with levels &gt;14 mcg/mL (median survival 24 versus 18 months, hazard ratio [HR] for death 0.52, 95% CI 0.28-0.97).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective study, therapeutic monitoring achieved better tolerance of adjuvant <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> therapy with fewer side effects [<a href="#rid103">103</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Furthermore, in the adjuvant setting, improved outcomes for patients with therapeutic <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> levels were shown in a report of 43 consecutive patients undergoing surgical treatment for ACC followed by monitored mitotane; 29 (67 percent) had stage III or IV tumors, and 33 underwent potentially curative surgery [<a href="#rid6">6</a>]. Four patients treated prior to 1990 (when mitotane monitoring was not available) received a low dose of the drug (1 g twice daily), while 13 others did not tolerate the drug and were kept at lower levels; 24 patients (75 percent of whom had stage III or IV tumors) were maintained at mitotane levels exceeding 14 mcg/mL. Despite the preponderance of stage III and IV tumors, the five-year disease-specific survival rate was high (64 percent). When the HR for death from ACC was compared over time between the patients with high mitotane levels versus the patients with lower doses or without mitotane treatment, there was a positive survival effect that persisted up to four years after surgery.</p><p></p><p>Every patient metabolizes <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> to different degrees and, hence, requires unique dosing to achieve therapeutic blood levels. Therapeutic serum levels can at times be achieved with low doses of mitotane. As an example, in one series of eight patients receiving 3 g daily (of the non-micronized formulation), therapeutic concentrations (14 to 20 mcg/mL) were reached in three to five months (after a cumulative dose of approximately 360 g), and five patients maintained clinical benefit (stable disease or disease free) with minimal toxicity for 8 to 40 months with as little as 1 to 2 g daily [<a href="#rid107">107</a>].</p><p>Inherited polymorphisms in drug-metabolizing enzymes have been described that may predict the individual response to adjuvant <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> [<a href="#rid108">108-110</a>]. However, at present, there is no defined clinical role for genotyping prior to the initiation of mitotane therapy in this or any other setting.</p><p>In the United States and Canada, plasma levels of <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> can be measured in commercial laboratories and some academic centers; in Europe, they are available through HRA Pharma, which distributes mitotane as an orphan drug. We recommend monitoring plasma mitotane levels in all patients, if possible, as outlined below.</p><p class="headingAnchor" id="H192296005"><span class="h3">Monitoring response</span></p><p class="headingAnchor" id="H68910287"><span class="h4">Imaging</span><span class="headingEndMark"> — </span>The efficacy of adjuvant <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> can be assessed periodically during therapy by the following techniques:</p><p class="bulletIndent1"><span class="glyph">●</span>Surveillance for recurrence of disease should include contrast-enhanced computed tomography (CT) scans (or magnetic resonance imaging [MRI]) of the chest, abdomen, and pelvis every three months for two to three years, then every four to six months for five years. (See  <a class="medical medical_review" href="/z/d/html/14613.html" rel="external">"Radiation-related risks of imaging"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although the role of fluorodeoxyglucose (FDG)-positron emission tomography (PET) in post-treatment monitoring is not yet established, some centers add integrated FDG-PET/CT at six-month intervals in the post-treatment follow-up strategy [<a href="#rid34">34</a>]. Limited studies comparing the usefulness of integrated PET/CT scans (which are typically done without intravenous [IV] contrast) versus diagnostic (ie, contrast-enhanced) CT performed at the same time have shown that integrated PET/CT detects more lesions than does PET or CT alone, and that PET should be considered a complementary examination to contrast-enhanced CT or MRI [<a href="#rid111">111-113</a>]. In one study, PET was more sensitive than CT in detecting local recurrence, while CT was more sensitive in detecting small lung or peritoneal metastases [<a href="#rid113">113</a>].</p><p></p><p class="bulletIndent1">Nevertheless, the utility of PET in the setting of primary treatment remains controversial. At the University of Michigan, PET is not performed routinely, either prior to primary surgery for a suspected ACC or as a component of the post-treatment surveillance strategy. However, other centers (including that of one of the authors [AL]) routinely perform PET prior to surgery for a suspected ACC and add integrated FDG-PET/CT at six-month intervals in the post-treatment follow-up strategy for patients with high-risk disease who have been shown to have FDG-avid disease preoperatively (see <a class="local">'Local therapy'</a> below). In more advanced disease, PET/CT may be preferred for assessment of chemotherapeutic response; in a small proportion of patients in one report, PET/CT predicted response before anatomic changes were detected on CT [<a href="#rid114">114</a>].</p><p></p><p class="headingAnchor" id="H68910294"><span class="h4">Biochemical</span><span class="headingEndMark"> — </span>For patients with a completely resected, steroid-producing ACC, some groups monitor for recurrent hormone excess every three months for two years with steroid tumor markers such as cortisol (measured in the morning before <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> dose), dehydroepiandrosterone sulfate (DHEAS), androstenedione, testosterone, estradiol, or mineralocorticoid based upon the steroid profile in the initial tumor. Other groups do not routinely screen for recurrent hormone excess unless or until there is evidence of recurrent disease.</p><p><a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">Mitotane</a>, which increases serum concentrations of corticosteroid-binding globulin (CBG), may result in serum cortisol values that are artifactually elevated [<a href="#rid115">115</a>] without significant changes in corticotropin (ACTH). Despite alterations in cortisol metabolism induced by mitotane, 24-hour urinary free cortisol excretion remains the best index of cortisol production currently available  (<a class="graphic graphic_table graphicRef83932" href="/z/d/graphic/83932.html" rel="external">table 3</a>) [<a href="#rid115">115</a>]. (See <a class="local">'Adrenal insufficiency'</a> below.)</p><p>Use of liquid chromatography-mass spectroscopy assays for urine cortisol and its metabolites should eventually offer better tools to assess steroid hormone production and requirements in ACC patients receiving <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> [<a href="#rid116">116</a>].</p><p class="headingAnchor" id="H8"><span class="h3">Toxicities</span></p><p class="headingAnchor" id="H19786739"><span class="h4">Side effects</span><span class="headingEndMark"> — </span>The toxicity profile of <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> limits tolerability, particularly at doses above 6 grams per day. The most common side effects are fatigue, nausea, vomiting, and anorexia, but skin rash, diarrhea, lethargy, sedation, confusion, dizziness, ataxia, gynecomastia, arthralgias, leukopenia, prolonged bleeding time, hematuria, and reversible growth arrest in children also occur [<a href="#rid15">15,117</a>].</p><p>Other adverse effects include frequent hyperlipidemia [<a href="#rid118">118</a>] (elevated low-density lipoprotein [LDL] cholesterol, high-density lipoprotein [HDL] cholesterol, triglycerides), hypouricemia, and hepatotoxicity  (<a class="graphic graphic_table graphicRef83932" href="/z/d/graphic/83932.html" rel="external">table 3</a>). If statins are used for the dyslipidemia, <a class="drug drug_general" data-topicid="9804" href="/z/d/drug information/9804.html" rel="external">pravastatin</a> and <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">rosuvastatin</a> should be considered as they have less drug interaction with <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a>.</p><p>While increased concentrations of serum GGT and alkaline phosphatase are almost invariably observed, a significant rise in transaminases or bilirubin is infrequent.</p><p class="headingAnchor" id="H1762852265"><span class="h4">Adrenal insufficiency</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">Mitotane</a> is a steroidogenesis inhibitor and adrenolytic drug. Glucocorticoid replacement therapy is necessary for patients treated with mitotane (unless the ACC is an advanced, glucocorticoid-producing tumor presenting as Cushing's syndrome). Independent of the pharmacologic effects of mitotane, for patients with cortisol-secreting ACC, suppression of ACTH-adrenal axis will require replacement with glucocorticoids following complete tumor resection. (See <a class="local">'Initial surgery'</a> above.)</p><p>Very long-term use of <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> usually induces atrophy and/or steroidogenic inhibition of the normal adrenal glands, thereby causing cortisol deficiency. The zona glomerulosa is more resistant to the adrenolytic effect of mitotane, and aldosterone deficiency may not occur until after several months of therapy. (See  <a class="medical medical_review" href="/z/d/html/119.html" rel="external">"Medical therapy of hypercortisolism (Cushing's syndrome)"</a>.)</p><p>Our approach to managing adrenal insufficiency includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initiate glucocorticoid therapy</strong> – We suggest starting replacement glucocorticoid therapy when <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> treatment is initiated because one cannot predict when a patient will become hypocortisolemic.</p><p></p><p class="bulletIndent1">For all patients who are receiving <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a>, we initiate replacement with <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> (30 to 40 mg daily in divided doses, two to three times per day). Of note, most patients eventually require a two- to threefold increase in hydrocortisone. Patients undergoing mitotane treatment should wear a medical alert bracelet and be instructed to increase their doses of hydrocortisone during stress.</p><p></p><p class="bulletIndent1">In patients with residual ACC and persistent hypercortisolemia, glucocorticoid replacement should <strong>not </strong>be<strong> </strong>initiated until hypercortisolism is controlled with <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> and steroid enzyme inhibitors. (See <a class="local">'Medical treatment of hormone excess'</a> below.)</p><p></p><p class="bulletIndent1">Several times the usual maintenance doses of glucocorticoids are sometimes needed as the induction of hepatic cytochrome P450 enzymes by <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> increases the rate of metabolism of cortisol, <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> [<a href="#rid119">119,120</a>], and <a class="drug drug_general" data-topicid="8455" href="/z/d/drug information/8455.html" rel="external">fludrocortisone</a>. Inadequately treated adrenal insufficiency enhances mitotane-induced side effects and reduces drug tolerance [<a href="#rid15">15,90,103</a>]. A brief trial of a higher glucocorticoid dose may mitigate some side effects that could be attributable to inadequate cortisol replacement and allow continuation of mitotane at the same dose.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – Close monitoring of blood sodium, potassium, creatinine, ACTH, and 24-hour urine free urinary cortisol levels is necessary to avoid adrenal insufficiency and acute hyperkalemia in patients treated with <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a>, whether in the adjuvant setting or for advanced disease  (<a class="graphic graphic_table graphicRef83932" href="/z/d/graphic/83932.html" rel="external">table 3</a>).</p><p></p><p class="bulletIndent1">Measurement of serum <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> levels together with 24-hour urine free cortisol with an assessment of side effects should guide mitotane and <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> dosing. If side effects do not abate with glucocorticoid therapy, temporary discontinuation of mitotane is indicated, followed by reinstitution at a lower dose. Measuring cortisol levels in hair may eventually become useful to assess chronic hydrocortisone replacement in ACC [<a href="#rid121">121</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aldosterone deficiency</strong> – <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">Mitotane</a> can also eventually cause aldosterone deficiency. Unlike glucocorticoid replacement, we do not start mineralocorticoid replacement right away. Instead, we suggest monitoring blood pressure at each visit, serum potassium at every three months, and plasma renin every six months  (<a class="graphic graphic_table graphicRef83932" href="/z/d/graphic/83932.html" rel="external">table 3</a>). Mineralocorticoid deficiency should be suspected if the patient develops postural hypotension, hyponatremia, or hyperkalemia and has an elevation in plasma renin activity.</p><p></p><p class="bulletIndent1">When clinical and biochemical signs of aldosterone deficiency become present, we suggest starting <a class="drug drug_general" data-topicid="8455" href="/z/d/drug information/8455.html" rel="external">fludrocortisone</a> (0.1 to 0.3 mg daily) to restore normal clinical and biochemical parameters  (<a class="graphic graphic_table graphicRef83932" href="/z/d/graphic/83932.html" rel="external">table 3</a>). As noted, the metabolism of fludrocortisone is increased by <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stopping </strong><strong>mitotane</strong><strong> and monitoring for recovery</strong> –<strong> </strong>After stopping <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> therapy, <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> therapy should be continued but progressively decreased to more physiologic levels (as mitotane acceleration of glucocorticoid metabolism returns to normal) until the patient has no clinical or biochemical evidence of adrenal insufficiency.</p><p></p><p class="bulletIndent1">Patients should be evaluated for potential recovery of adrenal insufficiency every six months by measuring morning levels of serum cortisol before intake of <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> replacement. Although adrenal insufficiency may become permanent in some patients, depending upon the duration of <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> therapy, it may recover in others. As an example, in a study of 23 patients with ACC treated with adjuvant mitotane for a minimum of two years, 18 of 23 (78 percent) patients achieved a complete hypothalamic-pituitary-adrenal (HPA) axis recovery within a mean interval of 2.7 years after discontinuing the adjuvant mitotane [<a href="#rid122">122</a>].</p><p></p><p class="headingAnchor" id="H718899"><span class="h4">Reproductive issues</span><span class="headingEndMark"> — </span>In men receiving <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> therapy, hypogonadism is common, often requiring replacement testosterone therapy. In addition to its effect on CBG, mitotane increases serum concentrations of other binding globulins, including sex hormone-binding globulin (SHBG) [<a href="#rid15">15,103</a>]. In addition to potential decreases in free testosterone levels, mitotane induces a strong inhibition of systemic 5-alpha-reductase activity, which may explain the relative inefficiency of testosterone replacement in mitotane-treated men [<a href="#rid120">120</a>]. Serum testosterone should be measured routinely in men receiving mitotane  (<a class="graphic graphic_table graphicRef83932" href="/z/d/graphic/83932.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/z/d/html/7462.html" rel="external">"Clinical features and diagnosis of male hypogonadism"</a> and  <a class="medical medical_review" href="/z/d/html/7461.html" rel="external">"Testosterone treatment of male hypogonadism"</a>.)</p><p>The impact of <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> on reproductive function in women is less clear. Increased levels of both luteinizing hormone (LH) and follicle-stimulating hormone (FSH) have been observed, which in some premenopausal women has resulted in the development of large ovarian cysts [<a href="#rid123">123</a>]. These cysts may be associated with lower abdomen discomfort and pain; cases of ovarian torsion requiring surgery have also been observed. (See  <a class="medical medical_review" href="/z/d/html/3305.html" rel="external">"Ovarian and fallopian tube torsion"</a>.)</p><p>There are concerns that pregnancy could lead to an increased likelihood of relapse, although data are minimal [<a href="#rid40">40</a>]. In addition, the safety of <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> during pregnancy is unknown. Therefore, for women of reproductive age scheduled to receive adjuvant mitotane therapy after ACC resection, we suggest contraception during and for at least one year after mitotane as the drug has a long half-life and is deposited in adipose tissues. We suggest barrier methods of contraception as mitotane accelerates steroid metabolism and may decrease the contraceptive efficacy of hormonal contraception. (See  <a class="medical medical_review" href="/z/d/html/5459.html" rel="external">"Contraception: Counseling and selection"</a>.)</p><p class="headingAnchor" id="H192296424"><span class="h4">Hypothyroidism</span><span class="headingEndMark"> — </span>In addition to its effect on CBG, <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> increases serum concentrations of other binding globulins, including thyroid hormone-binding globulin (TBG). Therefore, serum concentrations of free thyroxine (T4) may be decreased [<a href="#rid15">15,103</a>]. In addition, newer studies indicate a direct inhibitory effect of mitotane on secretion of thyroid-stimulating hormone (TSH) [<a href="#rid103">103</a>]. As patients on mitotane therapy often present with fatigue, thyroid function tests should be monitored periodically  (<a class="graphic graphic_table graphicRef83932" href="/z/d/graphic/83932.html" rel="external">table 3</a>). Hypothyroidism with low TSH is frequent, and free T4 should be monitored. Thyroid hormone replacement is suggested in patients with clinical symptoms of hypothyroidism and low free T4 values.</p><p class="headingAnchor" id="H1762852034"><span class="h3">Drug interactions</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">Mitotane</a> is a potent inducer of CYP3A4 metabolism. Limited data suggest that this can result in important drug-drug interactions [<a href="#rid124">124</a>]. In a report of two patients with ACC who were receiving mitotane in combination with <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> (a drug metabolized by CYP3A4), serum sunitinib concentrations were decreased by approximately 80 percent of expected values [<a href="#rid125">125</a>]. Although clinical data are currently unavailable, mitotane administration could reduce the efficacy of other drugs relevant to the management of patients with ACC, such as steroid hormone replacement, benzodiazepines, macrolide antibiotics, some opioids and statins, and dihydropyridine type calcium channel antagonists [<a href="#rid124">124</a>].</p><p>Specific interactions of <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> with other medications may be determined using <a class="external" href="/drug-interactions">Lexicomp drug interactions</a>.</p><p class="headingAnchor" id="H13"><span class="h2">Adjuvant radiation therapy</span><span class="headingEndMark"> — </span>Data on the usefulness of adjuvant radiation therapy following surgical resection has been limited by the retrospective nature of studies with small number of patients. The European Society of Endocrinology clinical practice guidelines panel suggest against the routine use of radiation therapy in patients with stage I to II and R0 resection. However, they suggest considering radiation in addition to <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> therapy in patients with R1 or Rx resection or in stage III [<a href="#rid1">1</a>].</p><p>We suggest the addition of postoperative radiation therapy (RT) for all patients with incompletely resected ACC, stage III disease with other characteristics of high recurrence risk, those who have tumor spillage at the time of resection, and for all patients with high-grade ACC (&gt;20 mitotic figures per 50 HPF). The benefit of adjuvant RT is limited to improved local control; no clear survival benefit has been shown except in one study. We suggest starting RT as soon as possible following surgery (ideally within 12 weeks).</p><p>In the past, ACC was thought to be a relatively radioresistant tumor. However, this is likely not true with modern RT techniques [<a href="#rid126">126</a>]. While there are no randomized trials testing the efficacy of adjuvant RT in patients with resected ACC, some, but not all, studies support a benefit in certain patients who are at high risk for a local recurrence [<a href="#rid126">126-132</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>One retrospective report addressing the benefit of adjuvant RT is from the German ACC registry [<a href="#rid127">127</a>]. Outcomes of 14 patients (stage I, II, and III  (<a class="graphic graphic_table graphicRef110639" href="/z/d/graphic/110639.html" rel="external">table 1</a>) in seven, three, and three patients, respectively) without macroscopic residual disease who received postoperative RT were compared with 14 others who did not receive RT and who were matched for resection status, use of adjuvant <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a>, stage, and tumor size. Local recurrence developed in 2 of 14 irradiated patients compared with 11 of 14 who did not receive RT. However, despite this apparent benefit, neither disease-free nor OS were significantly better in irradiated patients.</p><p></p><p class="bulletIndent1">A later analysis of patterns of failure in these patients suggested that many of the recurrences developed in the inter-aortocaval region [<a href="#rid126">126</a>]. This observation emphasizes the importance of covering this area in the radiation portal, as well as the ipsilateral lymphatic drainage bed, if adjuvant RT is planned.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective study from the University of Michigan compared outcomes of 20 patients with localized ACC undergoing an R0/R1 resection followed by postoperative RT (median dose 55 Gy) with those of 20 patients treated contemporaneously with surgery alone, matched for stage, surgical margin status, tumor grade, and use of adjuvant <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> [<a href="#rid129">129</a>]. At a median follow-up of 34 months, local recurrence was significantly more frequent in those not receiving RT, with local recurrence in 12 patients versus one (60 versus 5 percent, HR 12.59, 95% CI 1.62-97.88). As was seen in the German ACC registry analysis, this benefit did not translate into an improvement in RFS or OS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In contrast, in a retrospective study of 16 patients with ACC who had undergone either surgery followed by adjuvant RT (n = 16) or surgery only (n = 32), the rate of local recurrence was not significantly reduced by adjuvant RT (7 of 16 [44 percent] and 10 of 32 [31.3 percent] in the RT and control groups, respectively) [<a href="#rid133">133</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the largest single institution study (including 39 patients), gross surgical resection of ACC improved local RFS, all RFS, and OS in a propensity-matched analysis. Therefore, we suggest that adjuvant RT should be considered a part of multidisciplinary management for patients with ACC<strong> </strong>[<a href="#rid134">134</a>].</p><p></p><p>Larger, prospective, randomized studies are needed to better define the role of adjuvant RT after resection of ACC, in particular to confirm if the decrease in local recurrence rate provides any OS benefit.</p><p>Our approach is similar to that of the investigators from the German ACC registry, who recommended adjuvant RT for all patients with microscopically incomplete (R1 or R2) or uncertain (Rx) margin status and for those with stage III disease (according to ENSAT criteria  (<a class="graphic graphic_table graphicRef83901" href="/z/d/graphic/83901.html" rel="external">table 4</a>)) even if resection has been complete [<a href="#rid2">2,126</a>]. They suggest that adjuvant RT be considered for patients who have had a complete (R0) resection of a tumor &gt;8 cm in size with tumor invasion of the blood vessels (but not large tumor thrombus in the vena cava) and a Ki-67 proliferative index of &gt;10 percent, and for patients who have intraoperative violation of the tumor capsule, tumor spillage, or dissemination of "necrotic" fluid. Because the risk of a local recurrence is highest in the first two years, they recommend starting RT no later than three months after surgery.</p><p>There is disagreement as to the role of adjuvant RT in patients who have undergone laparoscopic rather than open resection, and there are no published data to help in resolving this point. There are different opinions regarding the safety and efficacy of laparoscopic resection of primary ACC. Thus, it is understandable that there are different opinions regarding the use of adjuvant RT in the setting of laparoscopic resection for a resected ACC that does not otherwise meet the criteria described above for adjuvant RT (tumor spillage at the time of resection, incompletely resected, high-grade lesion). The German ACC group does not recommend adjuvant RT in this situation.</p><p>The Adrenal Cancer Program at the University of Michigan, as reflected in the opinion of one of the authors (GH), does not recommend laparoscopic adrenalectomy for ACC and hence is more aggressive in recommending adjuvant RT following a laparoscopic resection of ACC if there is any concern that a sufficient oncologic resection was not performed. The other author (AL) does not pursue adjuvant RT after a laparoscopic resection (ACC at pathology, low ACC risk by preoperative investigation and German ACC criteria described above) as long as the laparoscopic surgery was performed by an expert surgeon (ie, one who specializes in and is trained in minimally invasive endocrine or oncology surgery, who practices in a large academic referral center, and who does adrenal surgery weekly).</p><p class="headingAnchor" id="H14"><span class="h1">RECURRENT OR ADVANCED ADRENOCORTICAL CANCER</span><span class="headingEndMark"> — </span>There is no curative therapy for metastatic or recurrent adrenocortical carcinoma (ACC). However, the symptoms of steroid excess can be controlled by medical therapy. In most cases, metastatic disease is fatal within one year, although there are rare long-term responses ascribed to chemotherapy with or without <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> [<a href="#rid1">1,117,135,136</a>].</p><p class="headingAnchor" id="H15"><span class="h2">Local therapy</span></p><p class="headingAnchor" id="H16"><span class="h3">Surgery</span><span class="headingEndMark"> — </span>For patients with isolated, locally recurrent ACC that is surgically accessible, we suggest complete surgical resection followed by <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> therapy.</p><p>Where complete removal is feasible, aggressive surgical resection of locally recurrent disease, with the aim of achieving negative surgical margins, should be undertaken [<a href="#rid75">75,86,137-139</a>]. The best candidates are those who have potentially resectable disease with a disease-free interval of at least one year after initial treatment.</p><p>Resection may also be considered in the rare patient who presents with synchronous limited, potentially resectable hepatic or pulmonary metastases [<a href="#rid140">140</a>]. Resection of locally recurrent disease may also be indicated for patients in whom surgery will be able to remove a majority of tumor burden or decrease severe hypercortisolism that is otherwise difficult to control; however, recovery from surgery may be slow, delaying administration of systemic therapy [<a href="#rid4">4</a>]. Thus, this approach should be limited to selected patients with uncontrollable symptomatic hormone excess or who are in imminent danger from organ invasion or compression.</p><p>Aggressive resection of locally recurrent or distant disease may prolong survival in some patients [<a href="#rid4">4,5,137-139,141,142</a>], and at least some reports suggest that long-term survival rates are higher among patients who undergo resection compared with those who do not [<a href="#rid74">74,137,140,143,144</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a series of 47 patients with ACC undergoing resection for locally recurrent or distant metastatic disease at Memorial Sloan-Kettering Cancer Center (MSKCC), five-year survival rates for patients with completely and incompletely resected locally recurrent disease were 57 and 0 percent, respectively [<a href="#rid137">137</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similar outcomes were reported in a series of 57 patients undergoing 116 procedures (23 for liver metastases, 48 for pulmonary metastases, 13 for metastases at other sites, 22 for abdominal disease including local recurrences) for recurrent or metastatic ACC [<a href="#rid144">144</a>]. Five-year survival was 41 percent, and median survival was significantly longer for those with a disease-free interval &gt;12 months (6.6 versus 1.7 years). The use of chemotherapy and <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> had no effect on survival.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another report of 28 patients undergoing resection for liver metastases from ACC (25 isolated, three with extrahepatic metastases), the five-year survival rate was 39 percent [<a href="#rid142">142</a>].</p><p></p><p>Response to neoadjuvant chemotherapy may be useful in defining which patients may benefit from surgical intervention. Radiofrequency ablation (RFA) is an alternative approach for these patients. (See <a class="local">'Radiofrequency ablation'</a> below.)</p><p class="headingAnchor" id="H17"><span class="h3">Radiation therapy</span><span class="headingEndMark"> — </span>For palliation of symptoms from locally advanced or distant metastatic disease (eg, a bone metastasis), we use palliative radiation therapy (RT). The available data support the palliative benefit of RT for unresectable local tumor that is causing local symptoms or for distant symptomatic metastases, such as in bone [<a href="#rid4">4,86,126,145-147</a>]. In a survey of published reports totaling 91 patients receiving palliative RT for advanced ACC from the German ACC registry, benefit (ie, pain relief, reduction in paresthesia or paralysis) was observed in 57 percent [<a href="#rid126">126</a>]. (See  <a class="medical medical_review" href="/z/d/html/2805.html" rel="external">"Radiation therapy for the management of painful bone metastases"</a>.)</p><p>Stereotactic radiosurgery may be beneficial for patients who have a good performance status and limited metastases to the brain, lung, or liver. (See  <a class="medical medical_review" href="/z/d/html/7063.html" rel="external">"Stereotactic cranial radiosurgery"</a> and  <a class="medical medical_review" href="/z/d/html/89528.html" rel="external">"Radiation therapy techniques in cancer treatment", section on 'Stereotactic radiation therapy techniques'</a>.)</p><p class="headingAnchor" id="H18"><span class="h3">Radiofrequency ablation</span><span class="headingEndMark"> — </span>Percutaneous RFA may provide short-term local control of an unresectable primary tumor, particularly for those &lt;5 cm in diameter [<a href="#rid4">4,148,149</a>]. The long-term impact on survival is unknown. RFA has also been used to treat small liver metastases [<a href="#rid148">148,150,151</a>].</p><p class="headingAnchor" id="H16810707"><span class="h2">Systemic therapy</span></p><p class="headingAnchor" id="H16810714"><span class="h3">Mitotane monotherapy</span><span class="headingEndMark"> — </span>Primary treatment with <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> may be indicated for patients who have histologically proven ACC in whom surgery is incomplete, not feasible, or contraindicated.</p><p>The quality of the available literature on <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> monotherapy is poor, and the results are highly variable. Most studies were conducted in early years without monitoring of tumor response with adequate imaging. Moreover, mitotane has often been given in a suboptimal way; much of the variability in outcomes may be attributable to subtherapeutic serum concentrations (see <a class="local">'Suggested regimen'</a> above). No data are available on survival or drug tolerance among patients with unresectable disease who are treated with an approach that includes monitoring of plasma mitotane concentrations (see <a class="local">'Suggested regimen'</a> above and <a class="local">'Toxicities'</a> above). Determinants of mitotane efficacy are unknown; CYP2W1<em>,</em> which is highly expressed in ACC, may represent a new predictive marker for the response to mitotane treatment [<a href="#rid108">108</a>].</p><p>Treatment benefits are generally short lived [<a href="#rid17">17,18</a>], and survival is not consistently prolonged. While there are isolated case reports of long-term disease control and rare cases of prolonged complete remission in patients with inoperable or metastatic disease [<a href="#rid117">117,152-154</a>], these are almost always patients with low-grade disease. In several studies of primary <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> therapy, the median survival was only 6.5 months [<a href="#rid83">83,155</a>], no different from that expected in untreated patients [<a href="#rid18">18,94,156</a>].</p><p>The main benefit of <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> for patients with unresectable advanced disease is usually reduction in symptoms of hypercortisolism (weakness, myopathy, diabetes, immunosuppression, insomnia). While a decrease in excess hormone production is reported in up to 75 percent of patients and tumor size is reduced in as many as one-third of cases [<a href="#rid83">83,92,93,155</a>], mitotane therapy alone is usually not sufficient to significantly decrease cortisol levels or have long-lasting effects on tumor growth. In a review of nine prospective series totaling 246 patients with advanced ACC (not restricted to primary therapy), the estimated mean objective regression rate with mitotane was only 26 percent [<a href="#rid15">15</a>]. Furthermore, some patients who have an objective response with mitotane are incapacitated by the side effects of the drug [<a href="#rid157">157</a>]. (See <a class="local">'Toxicities'</a> above.)</p><p>We reserve <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> monotherapy for the few patients who have a minimal burden (low number of tumor-involved organs) of low-grade (ie, low mitotic rate) disease and have recurred relatively late (two to three years) after surgery. These are the patients who are likely to have a prolonged survival [<a href="#rid54">54</a>]. In the setting of extensive (multiple tumor-involved organs), rapidly progressive, high-grade disease, mitotane is almost always administered in combination with cytotoxic chemotherapy because of a generally accepted view that response rates are higher. (See <a class="local">'Chemotherapy plus mitotane'</a> below.)</p><p>For patients with active disease and visible lesions, <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> is typically continued lifelong or until disease progression. However, several protocols for new targeted agents for ACC specifically require discontinuation of mitotane because of potentially detrimental drug interactions. Specific issues related to dosing, monitoring of serum levels during therapy, side effects, and drug interactions are addressed above. (See <a class="local">'Suggested regimen'</a> above and <a class="local">'Drug interactions'</a> above and <a class="local">'Toxicities'</a> above.)</p><p>For patients whose disease progresses while receiving adjuvant <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a>, or whose disease is high grade or rapidly progressing (on or off mitotane), our usual practice is to initiate cytotoxic chemotherapy, oftentimes while continuing mitotane, given the higher response rates.</p><p class="headingAnchor" id="H19"><span class="h2">Cytotoxic chemotherapy</span><span class="headingEndMark"> — </span>Many cytotoxic drugs have been studied in patients with advanced ACC, either alone or in combination with <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a>. Few non-mitotane-containing chemotherapy regimens have been tested in ACC, largely due to the rarity of the disease. Progress in therapy of advanced ACC has been limited by the rarity of the disease and the relatively small number of patients in each study.</p><p class="bulletIndent1"><span class="glyph">●</span>Although they are frequently used, single agents such as <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> or <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a> are associated with response rates that are generally less than 30 percent and of short duration [<a href="#rid158">158-160</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Results are disappointing for chemotherapy combinations when not combined with <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> [<a href="#rid161">161-166</a>].</p><p></p><p class="headingAnchor" id="H21"><span class="h3">Chemotherapy plus mitotane</span><span class="headingEndMark"> — </span>It is generally accepted, though not proven, that chemotherapy plus <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> produces better outcomes than does mitotane alone. Therefore, in the setting of extensive (multiple tumor-involved organs), rapidly progressive, high-grade disease, mitotane is almost always administered in combination with cytotoxic chemotherapy. For patients receiving combined therapy, we suggest mitotane in combination with <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a>, <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>, and <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> (EDP) as front-line therapy.</p><p><a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">Mitotane</a> increases the cytotoxic activity of other chemotherapeutic drugs on human adrenal carcinoma cells in vitro, possibly by acting as an antagonist of the multidrug resistance (MDR) protein, which is found in high concentrations in ACC, and functions as a drug efflux pump [<a href="#rid167">167,168</a>]. These data provide a rationale for combination therapy.</p><p>A few prospective trials have explored combination regimens that contain <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a>. Although no chemotherapy regimen has been shown to improve overall survival (OS) in patients with advanced ACC, some of the more encouraging results have been with the combination of EDP plus mitotane:</p><p class="bulletIndent1"><span class="glyph">●</span>An early study of EDP plus <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> in 72 ACC patients described an overall response rate of 49 percent [<a href="#rid169">169</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The largest trial of advanced ACC to date, the First International Randomized trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT), randomly assigned 304 patients with advanced ACC not amenable to radical surgery to <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> plus either EDP or streptozotocin [<a href="#rid170">170</a>]. Rates of objective tumor response (23 versus 9 percent) and median progression-free survival (5 versus 2.1 months) were both significantly better in the EDP-mitotane (EDP-M) group, although these benefits did not translate into a significantly prolonged survival (median 14.8 versus 12 months). This lack of significant difference in OS, despite better progression-free survival for EDP-M, is possibly due to the crossover design of the study since EDP-M was superior as a second-line treatment as well. Rates of serious adverse events did not differ significantly between treatments. The efficacy of both regimens as second-line therapy was similar to their efficacy as first-line therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Results with other chemotherapy drugs combined with <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> seem to be less promising [<a href="#rid81">81,171-174</a>].</p><p></p><p class="headingAnchor" id="H4164879"><span class="h3">Newer and investigational approaches</span><span class="headingEndMark"> — </span>Several novel approaches are under study for treatment of advanced ACC, many of which represent molecularly targeted therapies. These therapies have only been evaluated in the context of clinical trials, often after progression of disease on standard therapies (eg, <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> or EDP-mitotane).</p><p class="headingAnchor" id="H3529125310"><span class="h4">Immunotherapy</span><span class="headingEndMark"> — </span>Programmed cell death ligand (PD-L1) is expressed in some adrenocortical carcinomas (ACCs) and their associated tumor infiltrating lymphocytes, leading to interest in the use of checkpoint inhibitor immunotherapy in these patients. Further studies are needed to determine predictors of immunotherapy response in those with ACC as treatment appears effective regardless of microsatellite instability-high (MSI-H) status [<a href="#rid175">175</a>].</p><p><a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">Pembrolizumab</a> has shown a good safety profile and response rates ranging from 14 to 50 percent in phase II studies conducted in both adult and pediatric populations [<a href="#rid175">175-177</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In an open-label, single-arm phase II study, 39 adult patients with advanced ACC were treated with <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> [<a href="#rid175">175</a>]. A majority had received prior systemic therapy (either <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> or platinum-based chemotherapy). At a median follow-up of approximately 18 months, the objective response rate was 23 percent (9 patients); median progression-free and OS were 2 and 24 months respectively. Additionally, responses were seen in two of six patients with microsatellite instability high/mismatch repair deficient (MSI-H/MMR-D) tumors. Rates of grade ≥3 toxicity were low (13 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similar results were seen in another open-label, single-arm phase II trial. In this study, 16 adult patients with ACC refractory to previous therapies (approximately one-half with cortisol-producing tumors) were treated with the programmed death 1 (PD-1) inhibitor <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> [<a href="#rid176">176</a>]. At approximately seven-month follow-up, objective responses were seen in two patients (14 percent) and stable disease in seven patients (50 percent). Rates of grade ≥3 toxicities were low (13 percent), with only one patient discontinuing therapy due to pulmonary toxicity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a phase I-II open label trial of <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> (KEYNOTE-051), which enrolled 154 pediatric patients with various relapsed solid tumors, two of four patients with adrenocortical carcinoma achieved a partial response [<a href="#rid177">177</a>].</p><p></p><p class="headingAnchor" id="H3658634628"><span class="h4">Other approaches</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IGF1R inhibitors</strong> – Approximately 80 percent of ACCs overexpress insulin-like growth factor (IGF) type 2 (IGF-2), which is known to signal predominantly through the IGF-1 receptor (IGF1R).</p><p></p><p class="bulletIndent1">While preclinical and early phase studies of monoclonal antibodies or small molecules inhibiting IFG1R were initially promising [<a href="#rid178">178-181</a>], a subsequent phase I-II trial of the anti-IGF1R antibody cixutumumab demonstrated only limited overall efficacy [<a href="#rid182">182</a>]. Additionally, a placebo-controlled phase III trial of linsitinib, an oral small molecule of both the IGF1R and insulin receptor, did not demonstrate an improvement in disease-free or OS in patients with advanced ACC [<a href="#rid183">183</a>]. However, partial responses and disease stabilization in a subset of patients were observed with these drugs as single agents [<a href="#rid182">182-184</a>] and in combination with other drugs (such as <a class="drug drug_general" data-topicid="10344" href="/z/d/drug information/10344.html" rel="external">temsirolimus</a>) [<a href="#rid185">185</a>].</p><p></p><p class="bulletIndent1">Although we do not offer IGF1R inhibitors in patient with advanced ACC, further studies may determine molecular markers that can predict which patients may benefit from this approach.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>VEGF inhibitors</strong> – Vascular endothelial growth factor (VEGF) is upregulated in ACC tumor tissue, and some studies have found that circulating VEGF levels are significantly greater in patients with ACC as compared with those with adrenal adenomas.</p><p></p><p class="bulletIndent1">While case reports suggested activity of the antiangiogenic agents <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> [<a href="#rid186">186,187</a>], <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a>, and <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> [<a href="#rid186">186-189</a>], subsequent phase II trials have demonstrated limited efficacy of VEGF inhibitors both as single agents (eg, <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">axitinib</a> [<a href="#rid190">190</a>], sunitinib [<a href="#rid191">191</a>]), or in combination with chemotherapy (eg, <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> plus <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a> [<a href="#rid192">192</a>]; sorafenib plus weekly <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a> [<a href="#rid193">193</a>]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>EGFR inhibitors</strong> – The finding that over 80 percent of ACCs express the epidermal growth factor receptor (EGFR) [<a href="#rid194">194,195</a>] provides a rationale for the study of agents that target the EGFR. Unfortunately, salvage therapy with the small molecular EGFR inhibitor <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a> in combination with <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> was of little benefit in a trial of 10 assessable patients with advanced ACC who had failed at least two other systemic chemotherapy regimens [<a href="#rid196">196</a>]. Only one patient experienced a minor response, while eight patients experienced disease progression.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Radionuclide therapy</strong> – ACC can also be targeted with therapeutic radionuclides. Examples of active radionuclides include iodine-131-metomidate [<a href="#rid197">197</a>] and agents that target 11-beta-hydroxylase such as (R)-1-[1-(4-[131-I]iodophenyl)ethyl]-1H-imidazole-5-carboxylic acid azetidinyl ([iodine-131]-IMAZA) [<a href="#rid198">198</a>].</p><p></p><p class="headingAnchor" id="H23"><span class="h2">Medical treatment of hormone excess</span></p><p class="headingAnchor" id="H19786727"><span class="h3">Hypercortisolism</span><span class="headingEndMark"> — </span>Adrenal function should be closely monitored in patients with ACC because they can have either adrenal insufficiency (caused by surgery or <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a>) or excess cortisol secretion (caused by persistent or recurrent tumor). In patients with hypercortisolism (either those who are not taking mitotane or those whose hypercortisolism is not controlled by mitotane), addition of a more specific adrenal enzyme inhibitor is often required. Control of hypercortisolism is important as patients can die prematurely of infections related to immunosuppression induced by their hypercortisolism and chemotherapy rather than by tumor burden.</p><p>While there have been no published large series to determine which available steroidogenic enzyme inhibitors result in better control, we consider <a class="drug drug_general" data-topicid="10156" href="/z/d/drug information/10156.html" rel="external">metyrapone</a> as the first drug of choice in patients with ACC and hypercortisolism. While <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">ketoconazole</a> is effective in benign adrenal disease, it is our experience at the University of Michigan that it is rarely able to control the hypercortisolism in ACC.</p><p><a class="drug drug_general" data-topicid="10156" href="/z/d/drug information/10156.html" rel="external">Metyrapone</a>, which is now more easily available in North America (new distributor HRA Pharma, Paris, France, via its specialty pharmacy Direct Success Inc. with order form available on the web [<a href="#rid199">199</a>] or by phone at 1-855-674-7663), can be very effective in ACC, achieving eucortisolemia within three to seven days. If eucortisolism is not achieved with metyrapone, combination therapy with <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">ketoconazole</a> and <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> can be utilized. The choice of therapy has been influenced by different drug availability in various countries.</p><p>Medical therapy of hypercortisolism is reviewed in detail separately, but summarized briefly below (see  <a class="medical medical_review" href="/z/d/html/119.html" rel="external">"Medical therapy of hypercortisolism (Cushing's syndrome)"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with ACC, we suggest <a class="drug drug_general" data-topicid="10156" href="/z/d/drug information/10156.html" rel="external">metyrapone</a> starting at 250 mg four times daily and increasing up to 6 g per day.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If <a class="drug drug_general" data-topicid="10156" href="/z/d/drug information/10156.html" rel="external">metyrapone</a> alone is insufficient or not tolerated, <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">ketoconazole</a> is started at 200 mg three times/day, increasing daily as needed to 400 mg three times/day. Higher doses are seldom more effective.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Their effect can be assessed within a few days by measuring 24-hour urine cortisol on a frequent basis initially. Combination of both drugs and <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> may be necessary to achieve adequate control.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In severe uncontrolled cases, addition of <a class="drug drug_general" data-topicid="10263" href="/z/d/drug information/10263.html" rel="external">mifepristone</a>, a glucocorticoid receptor antagonist, can be beneficial [<a href="#rid200">200</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In acute situations with patients who are unable to take drugs orally, intravenous <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">etomidate</a> (which blocks 11-beta-hydroxylase) can be used in a low, nonhypnotic dose of 0.3 mg/kg per hour. However, this drug is difficult to use and requires inpatient monitoring. (See  <a class="medical medical_review" href="/z/d/html/119.html" rel="external">"Medical therapy of hypercortisolism (Cushing's syndrome)"</a>.)</p><p></p><p>Adrenal insufficiency is managed as described above using replacement mainly with <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a>. Aldosterone deficiency is replaced with addition of <a class="drug drug_general" data-topicid="8455" href="/z/d/drug information/8455.html" rel="external">fludrocortisone</a> (0.1 to 0.3 mg daily) and adjusted to restore normal blood pressure and serum levels of potassium and renin. (See <a class="local">'Adrenal insufficiency'</a> above.)</p><p>For patients who have increased hypercortisolism and are being treated with <a class="drug drug_general" data-topicid="10156" href="/z/d/drug information/10156.html" rel="external">metyrapone</a>, salt retention and hypertension can occur because of increased production of the mineralocorticoid deoxycorticosterone. We routinely use a mineralocorticoid receptor inhibitor (<a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> or <a class="drug drug_general" data-topicid="8789" href="/z/d/drug information/8789.html" rel="external">eplerenone</a>) or <a class="drug drug_general" data-topicid="8550" href="/z/d/drug information/8550.html" rel="external">amiloride</a> in this situation, adding diuretics and additional antihypertensive drugs if necessary.</p><p>When potassium-sparing diuretics are used in association with potassium supplements, frequent serum potassium monitoring is necessary as acute hyperkalemia can occur when hypercortisolism becomes controlled or when renal function is impaired. Adequate control of diabetes and high blood pressure are also important.</p><p class="headingAnchor" id="H19786733"><span class="h3">Other</span><span class="headingEndMark"> — </span>A small percentage of adult ACC and a high percentage of pediatric ACC often presents with virilization with/without hypercortisolism. Virilization is best treated with specific androgen blockage with androgen receptor inhibitors (<a class="drug drug_general" data-topicid="9154" href="/z/d/drug information/9154.html" rel="external">bicalutamide</a> at 50 mg per day) or 5-alpha-reductase inhibition (<a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">finasteride</a> at 5 mg per day).</p><p>While <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> is often used to control androgen effects in women with androgen excess in the setting of benign disease, it is often ineffective in the setting of ACC with very high serum androgen concentrations.</p><p>Rare estrogen-producing ACCs are treated with any of the antiestrogen therapies (such as <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a>). (See  <a class="medical medical_review" href="/z/d/html/7467.html" rel="external">"Management of gynecomastia", section on 'Pharmacologic therapy'</a>.)</p><p class="headingAnchor" id="H24"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Overall, survival is poor for adrenocortical carcinoma (ACC) [<a href="#rid16">16,17,41,48,50,75,86,87,137,201,202</a>]. Five-year survival is approximately 45 to 60 percent for early stage disease and 10 to 25 percent for advanced stage disease [<a href="#rid1">1</a>].</p><p>Past results suggested a poor prognosis even for patients with early stage disease [<a href="#rid11">11,17,25</a>]. However, some contemporary series suggest that outcomes are improving and that patients with these tumors are living longer [<a href="#rid41">41,50,87,137</a>], as illustrated by the following data:</p><p class="bulletIndent1"><span class="glyph">●</span>Among 139 adults treated for ACC over a 20-year period at MD Anderson Cancer Center, the five-year survival rate was 60 percent, despite the fact that 47 (34 percent) had distant metastases at diagnosis [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a second series of 113 patients treated at Memorial Sloan-Kettering Cancer Center (MSKCC), those who underwent complete resection of primary (not recurrent) disease (n = 68) had a five-year survival of 55 percent (median 74 months) [<a href="#rid137">137</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients followed closely after surgery for stage II ACC in specialized centers and who received adjuvant <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> had a much better prognosis than previously reported for this stage [<a href="#rid73">73</a>]. (See <a class="local">'Adjuvant mitotane'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The improved prognosis of treated patients in contemporary series can be illustrated by the previously described French Association of Endocrine Surgery series of 253 patients (age range 5 to 81 years, mean 47 years) with ACC treated between 1978 and 1997 [<a href="#rid41">41</a>]. The distribution by stage was as follows: stage I, 16; stage II, 126; stage III (locoregionally advanced disease), 57; stage IV (distant metastases only), 54 patients. Potentially curative surgery was performed in 182 (72 percent), and postoperative <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> was administered to 135 (54 percent) patients.</p><p></p><p class="bulletIndent1">Five-year survival rates were 38 percent overall and 50 percent in the curatively treated group. Stratified by disease stage, five-year survival rates were 66, 58, 24, and 0 percent for stage I, II, III, and IV (metastatic) disease, respectively. Despite no significant difference in the numbers of patients undergoing potentially curative surgery, outcomes were significantly better among those treated after 1988.</p><p></p><p>The reasons for the improved outcomes from treatment of ACC over time are not clear. Although the use of <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> increased over the 20-year time period, this had a significant impact on prognosis in multivariate analysis only for those patients who did not undergo potentially curative resection.</p><p class="headingAnchor" id="H2157877864"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H26"><span class="h2">Pediatric patients</span><span class="headingEndMark"> — </span>Pediatric patients with adrenocortical carcinoma (ACC) differ from adults in clinicopathologic characteristics, prognosis, and management.</p><p class="headingAnchor" id="H3491734376"><span class="h3">Clinicopathologic characteristics</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Familial cancer syndromes</strong> – Most children with adrenocortical tumors have associated familial cancer syndromes (mainly Beckwith-Wiedemann syndrome and Li-Fraumeni syndrome) [<a href="#rid203">203</a>]. (See  <a class="medical medical_review" href="/z/d/html/137.html" rel="external">"Clinical presentation and evaluation of adrenocortical tumors", section on 'Hereditary cancer syndromes'</a> and  <a class="medical medical_review" href="/z/d/html/14255.html" rel="external">"Li-Fraumeni syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/13555.html" rel="external">"Beckwith-Wiedemann syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histopathology</strong> – Unlike adults, severe histopathologic features in children, such as high Weiss score, are not reliable predictors of poor prognosis [<a href="#rid62">62</a>]. (See  <a class="medical medical_review" href="/z/d/html/137.html" rel="external">"Clinical presentation and evaluation of adrenocortical tumors", section on 'Fine-needle aspiration biopsy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Germline mutations in TP53</strong> – Approximately 50 percent or more of pediatric patients with ACCs in North America have germline mutations in the <em>TP53 </em>gene (which encodes the p53 tumor protein) [<a href="#rid204">204-206</a>]. In contrast, approximately 8 percent of adults have these mutations [<a href="#rid207">207</a>]. Loss of heterozygosity for 17p13 (the cytogenetic location of the <em>TP53</em> gene) occurs in 25 to 70 percent of sporadic ACCs [<a href="#rid207">207-210</a>].</p><p></p><p class="headingAnchor" id="H3436998972"><span class="h3">Prognosis</span><span class="headingEndMark"> — </span>The prognosis in children who have ACC appears to be better than that of adults, especially those for those with early-stage disease [<a href="#rid42">42,202,211-214</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In an observational series of 228 children and adolescents under age 20 with ACC, the estimated five-year event-free survival (EFS) rate was 54 percent overall; and for those with stage I or II disease, 91 and 53 percent, respectively [<a href="#rid42">42</a>]. Stage I disease (completely excised nonmetastatic tumors ≤200 g), presenting signs of virilization alone, and age less than three years were all associated with significantly better survival. In contrast, the prognosis was poor for patients with metastatic or residual disease or larger resected tumors (weighing more than 200 grams).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similar results were seen in an analysis of 85 patients with ACC under age 20 years reported to the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) database between 1973 and 2008 [<a href="#rid215">215</a>]. Younger patients (≤4 years old) were more likely to have favorable features than older patients (4 to 19 years), including local disease (76 versus 31 percent), tumor size &lt;10 cm (69 versus 31 percent), and better five-year survival (91 versus 30 percent). In multivariate analysis, the most significant independent predictors of disease-specific death were age greater than four years and distant disease. After accounting for tumor size, the only significant predictor of cancer-specific death was age 5 to 19 years.</p><p></p><p class="headingAnchor" id="H2445336574"><span class="h3">Management</span><span class="headingEndMark"> — </span>Because the clinicopathologic features and prognosis of ACC in pediatric patients differs from that of adults, they should be managed at a center with multidisciplinary expertise in pediatric ACC when possible [<a href="#rid205">205</a>]. An International Pediatric Adrenocortical Tumor Registry has been established to facilitate data collection, study, and treatment of these rare pediatric tumors [<a href="#rid212">212</a>].</p><p>There are limited prospective studies evaluating management strategies for pediatric patients with ACC.</p><p>A prospective, single-arm study from the Children's Oncology Group (ARAR0332) reported the survival outcomes of 78 pediatric patients with ACC who received different treatment strategies based on disease stage as follows [<a href="#rid206">206</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage I disease</strong> – Adrenalectomy alone</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage II disease</strong> – Adrenalectomy and retroperitoneal lymph node dissection</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage III or IV (metastatic) disease</strong> – <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">Mitotane</a> plus chemotherapy (<a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a>, <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>, and <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> [EDP]), followed by surgery of the primary tumor and metastases as clinically indicated</p><p></p><p>At median follow-up of 60 months, the five-year EFS and overall survival (OS) results were:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>All patients</strong> – 63 and 77 percent</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage I</strong> – 86 and 95 percent </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage II</strong> – 53 and 79 percent</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage III</strong> – 81 and 95 percent</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage IV</strong> – 7 and 16 percent</p><p></p><p>Approximately one-third (32 percent) of patients receiving <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> plus chemotherapy experienced significant treatment-related toxicity and could not complete scheduled therapy. Thus, although patients without metastatic disease who received chemotherapy (stage III disease) demonstrated improved survival compared with those treated with adrenalectomy and lymph node dissection alone (stage II disease), further treatment modifications may be necessary to improve chemotherapy tolerance. This difference in survival also suggests that lymph node dissection may not have been adequate to remove all micrometastases. Other possible explanations include increased efficacy of chemotherapy for treating micrometastases in stage III tumors, or more aggressive biology in stage II tumors.</p><p class="headingAnchor" id="H4135417173"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112784.html" rel="external">"Society guideline links: Adrenal cancer"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/112785.html" rel="external">"Society guideline links: Adrenal incidentaloma"</a>.)</p><p class="headingAnchor" id="H53956637"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/83148.html" rel="external">"Patient education: Adrenal cancer (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H28"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Adrenocortical carcinoma (ACC) is a rare but aggressive malignancy that can cause Cushing's syndrome, virilization, hyperaldosteronism, feminization, an abdominal mass, or no symptoms and be discovered incidentally. (See  <a class="medical medical_review" href="/z/d/html/137.html" rel="external">"Clinical presentation and evaluation of adrenocortical tumors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Past results suggest a poor prognosis even for patients with early stage adrenal cancer. However, some contemporary series suggest that patients with ACC are living longer. The reasons for the possible improvement in prognosis are unclear, but adjuvant <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> therapy appears to be beneficial. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial treatment, potentially resectable disease</strong> – The only potentially curative treatment for stage I to III ACC is surgical resection, and it is the initial approach, even if a complete resection cannot be achieved. (See <a class="local">'Initial surgery'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with stage I to III adrenocortical cancer who are surgical candidates, we suggest open rather than laparoscopic surgical resection, regardless of tumor size (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Suspicious lymph nodes should be resected, but the benefit of routine lymphadenectomy has not been fully established yet.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to adjuvant systemic therapy</strong> – Although resection is technically possible in most patients with stage I to III disease, it is not curative for many, presumably because occult micrometastases are present at the time of initial presentation. For all patients with completely resected ACC, our approach to adjuvant therapy is based upon risk of disease recurrence:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Low recurrence risk</strong> – For most patients at low risk of recurrence after complete resection (stage I to III, microscopically complete [R0] resection, Ki-67 ≤10 percent), we suggest observation rather than adjuvant <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>) as the addition of adjuvant mitotane failed to demonstrate statistically significant improvements in recurrence-free survival (RFS) or overall survival (OS) in a randomized trial. (See <a class="local">'Patients with low recurrence risk'</a> above.)</p><p></p><p class="bulletIndent2">We do offer adjuvant <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> to select patients who meet criteria for low-risk disease but also harbor some features that suggest a potential risk for recurrence. Examples include patients with stage III low-grade disease, or those with a large (&gt;20 cm) stage II tumor with a borderline mitotic rate or Ki-67 score.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>High recurrence risk</strong> – For those at high risk of disease recurrence after complete resection, we suggest adjuvant <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> therapy alone (without chemotherapy) rather than observation (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Clinical features that indicate a high risk of disease recurrence include high-grade disease (Ki-67 &gt;10 percent and &lt;20 percent or mitotic rate greater than 20 per 50 high-power fields [HPF]); incompletely resected disease; intraoperative tumor spillage or fracture; and large, low-grade tumors with vascular or capsular invasion. (See <a class="local">'Patients with high recurrence risk'</a> above and <a class="local">'Adjuvant mitotane'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Very high recurrence risk</strong> – For select patients at very high risk for an early recurrence (eg, very high Ki-67 staining (≥20 percent) and extensive vascular invasion/vena cava thrombus), we typically suggest the addition of cisplatin-based chemotherapy to <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>), although high-quality data are limited. (See <a class="local">'Patients with very high recurrence risk'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Indications for adjuvant radiation therapy</strong> – We suggest the addition of adjuvant radiation therapy (RT) for all patients with incompletely resected ACC, stage III disease with other characteristics of high recurrence risk, those who have tumor spillage at the time of resection, and for all patients with high-grade ACC (&gt;20 mitotic figures per 50 HPF) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Adjuvant radiation therapy'</a> above.)</p><p></p><p class="bulletIndent2">There is disagreement as to the role of adjuvant RT in patients who have undergone laparoscopic resection for an ACC that otherwise does not meet criteria for postoperative RT. (See <a class="local">'Radiation therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of adjuvant </strong><strong>mitotane</strong> – The optimal duration of adjuvant <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> therapy is not established and is based on the risk of disease recurrence, tolerance, and the maximal length of time the patient has achieved target therapeutic mitotane levels. (See <a class="local">'Duration'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most patients with resected low-risk ACC, observation is preferred. For those with indications for adjuvant therapy, we aim for a minimum of two years of <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with resected high-risk ACC, we treat with three to five years of adjuvant therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring for </strong><strong>mitotane</strong><strong> toxicities</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Target </strong><strong>mitotane</strong><strong> levels</strong> – If available, serum monitoring during <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> therapy should be used to achieve therapeutic levels and avoid toxicity. Mitotane levels should be maintained between 14 and 20 mcg/mL. (See <a class="local">'Suggested regimen'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Glucocorticoid replacement for adrenal insufficiency</strong> – Glucocorticoid replacement is necessary following resection of cortisol-secreting ACC. It should also be started in patients with non-cortisol-secreting tumors when adjuvant <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> therapy is initiated because the drug's adrenolytic activity will result in adrenal insufficiency in most patients. We use <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> rather than <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> for glucocorticoid coverage. Supraphysiologic doses become indicated because mitotane progressively accelerates cortisol metabolism by induction of the P450 system. (See <a class="local">'Adrenal insufficiency'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment of aldosterone deficiency</strong> – <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">Mitotane</a> can also eventually cause aldosterone deficiency. We suggest monitoring blood pressure at each visit, serum potassium at every three months, and plasma renin every six months  (<a class="graphic graphic_table graphicRef83932" href="/z/d/graphic/83932.html" rel="external">table 3</a>). When clinical and biochemical signs of aldosterone deficiency become present, addition of <a class="drug drug_general" data-topicid="8455" href="/z/d/drug information/8455.html" rel="external">fludrocortisone</a> (0.1 to 0.3 mg daily) is initiated and adjusted to restore normal clinical and biochemical parameters. (See <a class="local">'Adrenal insufficiency'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Post-treatment surveillance</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Imaging</strong> – Post-treatment surveillance includes computed tomography (CT) scans of the chest and abdomen every three months for two years, then every six months for five years. The benefit of fluorodeoxyglucose (FDG)-positron emission tomography (PET) in the post-treatment surveillance strategy is controversial, and practice is variable. (See <a class="local">'Imaging'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Biochemical monitoring</strong> – For patients with a completely resected, steroid-producing ACC, some groups monitor patients every three months for two years with steroid tumor markers such as cortisol (measured in the morning before <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> dose), dehydroepiandrosterone sulfate (DHEAS), androstenedione, testosterone, estradiol, or mineralocorticoid based on the steroid profile in the initial tumor. Other groups do not routinely screen for recurrent hormone excess unless or until there is evidence of recurrent disease. (See <a class="local">'Biochemical'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Unresectable, recurrent, or advanced disease</strong> – For patients with isolated, locally recurrent ACC that is surgically accessible, we suggest complete surgical resection followed by <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>) (see <a class="local">'Local therapy'</a> above). Resection may also be considered in the rare patient who presents with limited, potentially resectable hepatic or pulmonary metastases and for selected patients with uncontrollable symptomatic hormone excess. (See <a class="local">'Local therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most patients with unresectable disease, we suggest combined <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> plus chemotherapy rather than mitotane or chemotherapy alone (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). However, mitotane monotherapy is a reasonable option for patients with a limited burden of low-grade, slowly progressive disease. (See <a class="local">'Mitotane monotherapy'</a> above.)</p><p></p><p class="bulletIndent2">For patients receiving combined therapy, we suggest <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> in combination with <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a>, <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>, and <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> (EDP) rather than streptozotocin (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). If possible, patients should be referred to centers conducting randomized clinical trials. (See <a class="local">'Chemotherapy plus mitotane'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for</strong> <strong>radiofrequency ablation</strong> – Percutaneous radiofrequency ablation (RFA) may provide short-term local control of an unresectable primary tumor, particularly for those &lt;5 cm in diameter. (See <a class="local">'Radiofrequency ablation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medical treatment of hormone excess</strong> – In patients with hypercortisolism (who are either not taking <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> or whose hypercortisolism is not controlled by mitotane), we suggest <a class="drug drug_general" data-topicid="10156" href="/z/d/drug information/10156.html" rel="external">metyrapone</a> or, if necessary, its combined use with <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">ketoconazole</a> and mitotane to achieve control of hypercortisolism. Appropriate control of glucose, potassium levels, blood pressure, and infections are also important. (See <a class="local">'Medical treatment of hormone excess'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for palliative RT</strong> – For palliation of symptoms from locally advanced or distant metastatic disease (eg, a bone metastasis), we use palliative RT. (See <a class="local">'Radiation therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Investigational approaches</strong> – Progress in treating advanced ACC has been severely limited by the rarity of the disease. However, multicenter clinical trials for recurrent and advanced disease, several of which are studying molecularly targeted therapy, are in progress. (See <a class="local">'Newer and investigational approaches'</a> above.)</p><p></p><p class="headingAnchor" id="H2083405890"><span class="h1">DISCLOSURE</span><span class="headingEndMark"> — </span>The views expressed in this topic are those of the author(s) and do not reflect the official views or policy of the United States Government or its components.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Fassnacht M, Dekkers O, Else T, et al. European Society of Endocrinology Clinical Practice Guidelines on the Management of Adrenocortical Carcinoma in Adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 2018.</a></li><li><a class="nounderline abstract_t">Allolio B, Hahner S, Weismann D, Fassnacht M. Management of adrenocortical carcinoma. Clin Endocrinol (Oxf) 2004; 60:273.</a></li><li><a class="nounderline abstract_t">Fassnacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. J Clin Endocrinol Metab 2013; 98:4551.</a></li><li><a class="nounderline abstract_t">Schteingart DE, Doherty GM, Gauger PG, et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer 2005; 12:667.</a></li><li><a class="nounderline abstract_t">Crucitti F, Bellantone R, Ferrante A, et al. The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. Surgery 1996; 119:161.</a></li><li><a class="nounderline abstract_t">Wängberg B, Khorram-Manesh A, Jansson S, et al. The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane. Endocr Relat Cancer 2010; 17:265.</a></li><li><a class="nounderline abstract_t">Harrison LE, Gaudin PB, Brennan MF. Pathologic features of prognostic significance for adrenocortical carcinoma after curative resection. Arch Surg 1999; 134:181.</a></li><li><a class="nounderline abstract_t">Reibetanz J, Jurowich C, Erdogan I, et al. Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma. Ann Surg 2012; 255:363.</a></li><li><a class="nounderline abstract_t">Gerry JM, Tran TB, Postlewait LM, et al. Lymphadenectomy for Adrenocortical Carcinoma: Is There a Therapeutic Benefit? Ann Surg Oncol 2016; 23:708.</a></li><li><a class="nounderline abstract_t">Reibetanz J, Rinn B, Kunz AS, et al. Patterns of Lymph Node Recurrence in Adrenocortical Carcinoma: Possible Implications for Primary Surgical Treatment. Ann Surg Oncol 2019; 26:531.</a></li><li><a class="nounderline abstract_t">Bertagna C, Orth DN. Clinical and laboratory findings and results of therapy in 58 patients with adrenocortical tumors admitted to a single medical center (1951 to 1978). Am J Med 1981; 71:855.</a></li><li><a class="nounderline abstract_t">Stojadinovic A, Ghossein RA, Hoos A, et al. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol 2002; 20:941.</a></li><li><a class="nounderline abstract_t">Hough AJ, Hollifield JW, Page DL, Hartmann WH. Prognostic factors in adrenal cortical tumors. A mathematical analysis of clinical and morphologic data. Am J Clin Pathol 1979; 72:390.</a></li><li><a class="nounderline abstract_t">Schteingart DE, Motazedi A, Noonan RA, Thompson NW. Treatment of adrenal carcinomas. Arch Surg 1982; 117:1142.</a></li><li><a class="nounderline abstract_t">Allolio B, Fassnacht M. Clinical review: Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 2006; 91:2027.</a></li><li><a class="nounderline abstract_t">Abiven G, Coste J, Groussin L, et al. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab 2006; 91:2650.</a></li><li><a class="nounderline abstract_t">Luton JP, Cerdas S, Billaud L, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990; 322:1195.</a></li><li><a class="nounderline abstract_t">MACFARLANE DA. Cancer of the adrenal cortex; the natural history, prognosis and treatment in a study of fifty-five cases. Ann R Coll Surg Engl 1958; 23:155.</a></li><li><a class="nounderline abstract_t">Gröndal S, Cedermark B, Eriksson B, et al. Adrenocortical carcinoma. A retrospective study of a rare tumor with a poor prognosis. Eur J Surg Oncol 1990; 16:500.</a></li><li><a class="nounderline abstract_t">Thompson NW, Cheung PS. Diagnosis and treatment of functioning and nonfunctioning adrenocortical neoplasms including incidentalomas. Surg Clin North Am 1987; 67:423.</a></li><li><a class="nounderline abstract_t">Srougi V, Bancos I, Daher M, et al. Cytoreductive Surgery of the Primary Tumor in Metastatic Adrenocortical Carcinoma: Impact on Patients' Survival. J Clin Endocrinol Metab 2022; 107:964.</a></li><li><a class="nounderline abstract_t">Hogan TF, Gilchrist KW, Westring DW, Citrin DL. A clinical and pathological study of adrenocortical carcinoma: therapeutic implications. Cancer 1980; 45:2880.</a></li><li><a class="nounderline abstract_t">Wajchenberg BL, Albergaria Pereira MA, Medonca BB, et al. Adrenocortical carcinoma: clinical and laboratory observations. Cancer 2000; 88:711.</a></li><li><a class="nounderline abstract_t">Zografos GC, Driscoll DL, Karakousis CP, Huben RP. Adrenal adenocarcinoma: a review of 53 cases. J Surg Oncol 1994; 55:160.</a></li><li><a class="nounderline abstract_t">Ng L, Libertino JM. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Urol 2003; 169:5.</a></li><li><a class="nounderline abstract_t">Bednarski BK, Habra MA, Phan A, et al. Borderline resectable adrenal cortical carcinoma: a potential role for preoperative chemotherapy. World J Surg 2014; 38:1318.</a></li><li><a class="nounderline abstract_t">Henry JF, Sebag F, Iacobone M, Mirallie E. Results of laparoscopic adrenalectomy for large and potentially malignant tumors. World J Surg 2002; 26:1043.</a></li><li><a class="nounderline abstract_t">Kebebew E, Siperstein AE, Clark OH, Duh QY. Results of laparoscopic adrenalectomy for suspected and unsuspected malignant adrenal neoplasms. Arch Surg 2002; 137:948.</a></li><li><a class="nounderline abstract_t">Lombardi CP, Raffaelli M, De Crea C, Bellantone R. Role of laparoscopy in the management of adrenal malignancies. J Surg Oncol 2006; 94:128.</a></li><li><a class="nounderline abstract_t">Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 2016; 175:G1.</a></li><li><a class="nounderline abstract_t">Miller BS, Ammori JB, Gauger PG, et al. Laparoscopic resection is inappropriate in patients with known or suspected adrenocortical carcinoma. World J Surg 2010; 34:1380.</a></li><li><a class="nounderline abstract_t">Prager G, Heinz-Peer G, Passler C, et al. Applicability of laparoscopic adrenalectomy in a prospective study in 150 consecutive patients. Arch Surg 2004; 139:46.</a></li><li><a class="nounderline abstract_t">Gonzalez RJ, Shapiro S, Sarlis N, et al. Laparoscopic resection of adrenal cortical carcinoma: a cautionary note. Surgery 2005; 138:1078.</a></li><li><a class="nounderline abstract_t">Zini L, Porpiglia F, Fassnacht M. Contemporary management of adrenocortical carcinoma. Eur Urol 2011; 60:1055.</a></li><li><a class="nounderline abstract_t">Brix D, Allolio B, Fenske W, et al. Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. Eur Urol 2010; 58:609.</a></li><li><a class="nounderline abstract_t">McCauley LR, Nguyen MM. Laparoscopic radical adrenalectomy for cancer: long-term outcomes. Curr Opin Urol 2008; 18:134.</a></li><li><a class="nounderline abstract_t">Porpiglia F, Fiori C, Daffara F, et al. Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer. Eur Urol 2010; 57:873.</a></li><li><a class="nounderline abstract_t">Sgourakis G, Lanitis S, Kouloura A, et al. Laparoscopic versus Open Adrenalectomy for Stage I/II Adrenocortical Carcinoma: Meta-Analysis of Outcomes. J Invest Surg 2015; 28:145.</a></li><li><a class="nounderline abstract_t">Porpiglia F, Miller BS, Manfredi M, et al. A debate on laparoscopic versus open adrenalectomy for adrenocortical carcinoma. Horm Cancer 2011; 2:372.</a></li><li><a class="nounderline abstract_t">Else T, Kim AC, Sabolch A, et al. Adrenocortical carcinoma. Endocr Rev 2014; 35:282.</a></li><li><a class="nounderline abstract_t">Icard P, Goudet P, Charpenay C, et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg 2001; 25:891.</a></li><li><a class="nounderline abstract_t">Michalkiewicz E, Sandrini R, Figueiredo B, et al. Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. J Clin Oncol 2004; 22:838.</a></li><li><a class="nounderline abstract_t">Lucon AM, Pereira MA, Mendonça BB, et al. Adrenocortical tumors: results of treatment and study of Weiss's score as a prognostic factor. Rev Hosp Clin Fac Med Sao Paulo 2002; 57:251.</a></li><li><a class="nounderline abstract_t">Wieneke JA, Thompson LD, Heffess CS. Adrenal cortical neoplasms in the pediatric population: a clinicopathologic and immunophenotypic analysis of 83 patients. Am J Surg Pathol 2003; 27:867.</a></li><li><a class="nounderline abstract_t">Clay MR, Pinto EM, Fishbein L, et al. Pathological and Genetic Stratification for Management of Adrenocortical Carcinoma. J Clin Endocrinol Metab 2022; 107:1159.</a></li><li><a class="nounderline abstract_t">Miller BS, Gauger PG, Hammer GD, et al. Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade. Langenbecks Arch Surg 2010; 395:955.</a></li><li><a class="nounderline abstract_t">Asare EA, Wang TS, Winchester DP, et al. A novel staging system for adrenocortical carcinoma better predicts survival in patients with stage I/II disease. Surgery 2014; 156:1378.</a></li><li><a class="nounderline abstract_t">Bilimoria KY, Shen WT, Elaraj D, et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer 2008; 113:3130.</a></li><li><a class="nounderline abstract_t">Weiss LM, Medeiros LJ, Vickery AL Jr. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 1989; 13:202.</a></li><li><a class="nounderline abstract_t">Vassilopoulou-Sellin R, Schultz PN. Adrenocortical carcinoma. Clinical outcome at the end of the 20th century. Cancer 2001; 92:1113.</a></li><li><a class="nounderline abstract_t">Volante M, Bollito E, Sperone P, et al. Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification. Histopathology 2009; 55:535.</a></li><li><a class="nounderline abstract_t">Berruti A, Fassnacht M, Baudin E, et al. Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel. J Clin Oncol 2010; 28:e401.</a></li><li><a class="nounderline abstract_t">Morimoto R, Satoh F, Murakami O, et al. Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas. Endocr J 2008; 55:49.</a></li><li><a class="nounderline abstract_t">Assié G, Antoni G, Tissier F, et al. Prognostic parameters of metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 2007; 92:148.</a></li><li><a class="nounderline abstract_t">Beuschlein F, Weigel J, Saeger W, et al. Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. J Clin Endocrinol Metab 2015; 100:841.</a></li><li><a class="nounderline abstract_t">de Reyniès A, Assié G, Rickman DS, et al. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol 2009; 27:1108.</a></li><li><a class="nounderline abstract_t">Giordano TJ, Kuick R, Else T, et al. Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin Cancer Res 2009; 15:668.</a></li><li><a class="nounderline abstract_t">Fragoso MC, Almeida MQ, Mazzuco TL, et al. Combined expression of BUB1B, DLGAP5, and PINK1 as predictors of poor outcome in adrenocortical tumors: validation in a Brazilian cohort of adult and pediatric patients. Eur J Endocrinol 2012; 166:61.</a></li><li><a class="nounderline abstract_t">Assié G, Letouzé E, Fassnacht M, et al. Integrated genomic characterization of adrenocortical carcinoma. Nat Genet 2014; 46:607.</a></li><li><a class="nounderline abstract_t">Ross JS, Wang K, Rand JV, et al. Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies. J Clin Pathol 2014; 67:968.</a></li><li><a class="nounderline abstract_t">Zheng S, Cherniack AD, Dewal N, et al. Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell 2016; 29:723.</a></li><li><a class="nounderline abstract_t">Faria AM, Almeida MQ. Differences in the molecular mechanisms of adrenocortical tumorigenesis between children and adults. Mol Cell Endocrinol 2012; 351:52.</a></li><li><a class="nounderline abstract_t">Ronchi CL, Sbiera S, Leich E, et al. Low SGK1 expression in human adrenocortical tumors is associated with ACTH-independent glucocorticoid secretion and poor prognosis. J Clin Endocrinol Metab 2012; 97:E2251.</a></li><li><a class="nounderline abstract_t">Gaujoux S, Grabar S, Fassnacht M, et al. β-catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma. Clin Cancer Res 2011; 17:328.</a></li><li><a class="nounderline abstract_t">Ragazzon B, Libé R, Gaujoux S, et al. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers. Cancer Res 2010; 70:8276.</a></li><li><a class="nounderline abstract_t">Giordano TJ, Thomas DG, Kuick R, et al. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol 2003; 162:521.</a></li><li><a class="nounderline abstract_t">Sbiera S, Schmull S, Assie G, et al. High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. J Clin Endocrinol Metab 2010; 95:E161.</a></li><li><a class="nounderline abstract_t">Heaton JH, Wood MA, Kim AC, et al. Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and β-catenin. Am J Pathol 2012; 181:1017.</a></li><li><a class="nounderline abstract_t">Mohan DR, Lerario AM, Else T, et al. Targeted Assessment of G0S2 Methylation Identifies a Rapidly Recurrent, Routinely Fatal Molecular Subtype of Adrenocortical Carcinoma. Clin Cancer Res 2019; 25:3276.</a></li><li><a class="nounderline abstract_t">Libè R, Fratticci A, Bertherat J. Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer 2007; 14:13.</a></li><li><a class="nounderline abstract_t">Fassnacht M, Allolio B. What is the best approach to an apparently nonmetastatic adrenocortical carcinoma? Clin Endocrinol (Oxf) 2010; 73:561.</a></li><li><a class="nounderline abstract_t">Berruti A, Fassnacht M, Libe R, et al. First randomized trial on adjuvant mitotane in adrenocortical carcinoma patients: The Adjuvo study. J Clin Oncol 2022; 40;6S.</a></li><li><a class="nounderline abstract_t">Fassnacht M, Johanssen S, Fenske W, et al. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. J Clin Endocrinol Metab 2010; 95:4925.</a></li><li><a class="nounderline abstract_t">Pommier RF, Brennan MF. An eleven-year experience with adrenocortical carcinoma. Surgery 1992; 112:963.</a></li><li><a class="nounderline abstract_t">Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 2007; 356:2372.</a></li><li><a class="nounderline abstract_t">Fassnacht M, Libé R, Kroiss M, Allolio B. Adrenocortical carcinoma: a clinician's update. Nat Rev Endocrinol 2011; 7:323.</a></li><li class="breakAll">National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Available at: https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf (Accessed on July 25, 2023).</li><li><a class="nounderline abstract_t">Giordano TJ. The argument for mitotic rate-based grading for the prognostication of adrenocortical carcinoma. Am J Surg Pathol 2011; 35:471.</a></li><li><a class="nounderline abstract_t">Kimpel O, Bedrose S, Megerle F, et al. Adjuvant platinum-based chemotherapy in radically resected adrenocortical carcinoma: a cohort study. Br J Cancer 2021; 125:1233.</a></li><li><a class="nounderline abstract_t">Hovi L, Wikström S, Vettenranta K, et al. Adrenocortical carcinoma in children: a role for etoposide and cisplatin adjuvant therapy? Preliminary report. Med Pediatr Oncol 2003; 40:324.</a></li><li><a class="nounderline abstract_t">Khan TS, Imam H, Juhlin C, et al. Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann Oncol 2000; 11:1281.</a></li><li><a class="nounderline abstract_t">Henley DJ, van Heerden JA, Grant CS, et al. Adrenal cortical carcinoma--a continuing challenge. Surgery 1983; 94:926.</a></li><li><a class="nounderline abstract_t">Hutter AM Jr, Kayhoe DE. Adrenal cortical carcinoma. Clinical features of 138 patients. Am J Med 1966; 41:572.</a></li><li><a class="nounderline abstract_t">Nader S, Hickey RC, Sellin RV, Samaan NA. Adrenal cortical carcinoma. A study of 77 cases. Cancer 1983; 52:707.</a></li><li><a class="nounderline abstract_t">Khorram-Manesh A, Ahlman H, Jansson S, et al. Adrenocortical carcinoma: surgery and mitotane for treatment and steroid profiles for follow-up. World J Surg 1998; 22:605.</a></li><li><a class="nounderline abstract_t">Kopf D, Goretzki PE, Lehnert H. Clinical management of malignant adrenal tumors. J Cancer Res Clin Oncol 2001; 127:143.</a></li><li><a class="nounderline abstract_t">Kendrick ML, Lloyd R, Erickson L, et al. Adrenocortical carcinoma: surgical progress or status quo? Arch Surg 2001; 136:543.</a></li><li><a class="nounderline abstract_t">Kasperlik-Załuska AA, Migdalska BM, Zgliczyński S, Makowska AM. Adrenocortical carcinoma. A clinical study and treatment results of 52 patients. Cancer 1995; 75:2587.</a></li><li><a class="nounderline abstract_t">Dickstein G, Shechner C, Arad E, et al. Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma? J Clin Endocrinol Metab 1998; 83:3100.</a></li><li><a class="nounderline abstract_t">Kasperlik-Zaluska AA. Clinical results of the use of mitotane for adrenocortical carcinoma. Braz J Med Biol Res 2000; 33:1191.</a></li><li><a class="nounderline abstract_t">Schteingart DE. Adjuvant mitotane therapy of adrenal cancer - use and controversy. N Engl J Med 2007; 356:2415.</a></li><li><a class="nounderline abstract_t">Vassilopoulou-Sellin R, Guinee VF, Klein MJ, et al. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer 1993; 71:3119.</a></li><li><a class="nounderline abstract_t">Baudin E, Pellegriti G, Bonnay M, et al. Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 2001; 92:1385.</a></li><li><a class="nounderline abstract_t">Bodie B, Novick AC, Pontes JE, et al. The Cleveland Clinic experience with adrenal cortical carcinoma. J Urol 1989; 141:257.</a></li><li><a class="nounderline abstract_t">Barzon L, Fallo F, Sonino N, et al. Adrenocortical carcinoma: experience in 45 patients. Oncology 1997; 54:490.</a></li><li><a class="nounderline abstract_t">Haak HR, Hermans J, van de Velde CJ, et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 1994; 69:947.</a></li><li><a class="nounderline abstract_t">Barzon L, Fallo F, Sonino N, et al. Comment--Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma? J Clin Endocrinol Metab 1999; 84:1488.</a></li><li><a class="nounderline abstract_t">Berruti A, Grisanti S, Pulzer A, et al. Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma. J Clin Endocrinol Metab 2017; 102:1358.</a></li><li><a class="nounderline abstract_t">Else T, Williams AR, Sabolch A, et al. Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab 2014; 99:455.</a></li><li><a class="nounderline abstract_t">Calabrese A, Basile V, Puglisi S, et al. Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence. Eur J Endocrinol 2019; 180:387.</a></li><li><a class="nounderline abstract_t">van Slooten H, Moolenaar AJ, van Seters AP, Smeenk D. The treatment of adrenocortical carcinoma with o,p'-DDD: prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol 1984; 20:47.</a></li><li><a class="nounderline abstract_t">Mauclère-Denost S, Leboulleux S, Borget I, et al. High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up. Eur J Endocrinol 2012; 166:261.</a></li><li><a class="nounderline abstract_t">Daffara F, De Francia S, Reimondo G, et al. Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocr Relat Cancer 2008; 15:1043.</a></li><li><a class="nounderline abstract_t">Hermsen IG, Fassnacht M, Terzolo M, et al. Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. J Clin Endocrinol Metab 2011; 96:1844.</a></li><li><a class="nounderline abstract_t">Kasperlik-Zaluska AA, Cichocki A. Clinical role of determination of plasma mitotane and its metabolites levels in patients with adrenal cancer: results of a long-term follow-up. J Exp Ther Oncol 2005; 5:125.</a></li><li><a class="nounderline abstract_t">Terzolo M, Baudin AE, Ardito A, et al. Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection. Eur J Endocrinol 2013; 169:263.</a></li><li><a class="nounderline abstract_t">Terzolo M, Pia A, Berruti A, et al. Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer. J Clin Endocrinol Metab 2000; 85:2234.</a></li><li><a class="nounderline abstract_t">Ronchi CL, Sbiera S, Volante M, et al. CYP2W1 is highly expressed in adrenal glands and is positively associated with the response to mitotane in adrenocortical carcinoma. PLoS One 2014; 9:e105855.</a></li><li><a class="nounderline abstract_t">D'Avolio A, De Francia S, Basile V, et al. Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane. Pharmacogenet Genomics 2013; 23:293.</a></li><li><a class="nounderline abstract_t">Kerkhofs TM, Derijks LJ, Ettaieb MH, et al. Short-term variation in plasma mitotane levels confirms the importance of trough level monitoring. Eur J Endocrinol 2014; 171:677.</a></li><li><a class="nounderline abstract_t">Mackie GC, Shulkin BL, Ribeiro RC, et al. Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 2006; 91:2665.</a></li><li><a class="nounderline abstract_t">Leboulleux S, Dromain C, Bonniaud G, et al. Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. J Clin Endocrinol Metab 2006; 91:920.</a></li><li><a class="nounderline abstract_t">Deandreis D, Leboulleux S, Caramella C, et al. FDG PET in the management of patients with adrenal masses and adrenocortical carcinoma. Horm Cancer 2011; 2:354.</a></li><li><a class="nounderline abstract_t">Takeuchi S, Balachandran A, Habra MA, et al. Impact of ¹⁸F-FDG PET/CT on the management of adrenocortical carcinoma: analysis of 106 patients. Eur J Nucl Med Mol Imaging 2014; 41:2066.</a></li><li><a class="nounderline abstract_t">van Seters AP, Moolenaar AJ. Mitotane increases the blood levels of hormone-binding proteins. Acta Endocrinol (Copenh) 1991; 124:526.</a></li><li><a class="nounderline abstract_t">Arlt W, Biehl M, Taylor AE, et al. Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. J Clin Endocrinol Metab 2011; 96:3775.</a></li><li><a class="nounderline abstract_t">De León DD, Lange BJ, Walterhouse D, Moshang T. Long-term (15 years) outcome in an infant with metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 2002; 87:4452.</a></li><li><a class="nounderline abstract_t">Gagnon N, Bernard S, Paquette M, et al. Characterization of hyperlipidemia secondary to mitotane in adrenocortical carcinoma. Endocr Oncol 2022; 2:1.</a></li><li><a class="nounderline abstract_t">Robinson BG, Hales IB, Henniker AJ, et al. The effect of o,p'-DDD on adrenal steroid replacement therapy requirements. Clin Endocrinol (Oxf) 1987; 27:437.</a></li><li><a class="nounderline abstract_t">Chortis V, Taylor AE, Schneider P, et al. Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement. J Clin Endocrinol Metab 2013; 98:161.</a></li><li><a class="nounderline abstract_t">Manenschijn L, Quinkler M, van Rossum EF. Hair cortisol measurement in mitotane-treated adrenocortical cancer patients. Horm Metab Res 2014; 46:299.</a></li><li><a class="nounderline abstract_t">Poirier J, Gagnon N, Terzolo M, et al. Recovery of Adrenal Insufficiency Is Frequent After Adjuvant Mitotane Therapy in Patients with Adrenocortical Carcinoma. Cancers (Basel) 2020; 12:639.</a></li><li><a class="nounderline abstract_t">Salenave S, Bernard V, Do Cao C, et al. Ovarian macrocysts and gonadotrope-ovarian axis disruption in premenopausal women receiving mitotane for adrenocortical carcinoma or Cushing's disease. Eur J Endocrinol 2015; 172:141.</a></li><li><a class="nounderline abstract_t">Kroiss M, Quinkler M, Lutz WK, et al. Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. Clin Endocrinol (Oxf) 2011; 75:585.</a></li><li><a class="nounderline abstract_t">van Erp NP, Guchelaar HJ, Ploeger BA, et al. Mitotane has a strong and a durable inducing effect on CYP3A4 activity. Eur J Endocrinol 2011; 164:621.</a></li><li><a class="nounderline abstract_t">Polat B, Fassnacht M, Pfreundner L, et al. Radiotherapy in adrenocortical carcinoma. Cancer 2009; 115:2816.</a></li><li><a class="nounderline abstract_t">Fassnacht M, Hahner S, Polat B, et al. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab 2006; 91:4501.</a></li><li><a class="nounderline abstract_t">Markoe AM, Serber W, Micaily B, Brady LW. Radiation therapy for adjunctive treatment of adrenal cortical carcinoma. Am J Clin Oncol 1991; 14:170.</a></li><li><a class="nounderline abstract_t">Sabolch A, Else T, Griffith KA, et al. Adjuvant radiation therapy improves local control after surgical resection in patients with localized adrenocortical carcinoma. Int J Radiat Oncol Biol Phys 2015; 92:252.</a></li><li><a class="nounderline abstract_t">Nelson DW, Chang SC, Bandera BC, et al. Adjuvant Radiation is Associated with Improved Survival for Select Patients with Non-metastatic Adrenocortical Carcinoma. Ann Surg Oncol 2018; 25:2060.</a></li><li><a class="nounderline abstract_t">Viani GA, Viana BS. Adjuvant radiotherapy after surgical resection for adrenocortical carcinoma: A systematic review of observational studies and meta-analysis. J Cancer Res Ther 2019; 15:S20.</a></li><li><a class="nounderline abstract_t">Wu K, Liu X, Liu Z, et al. Benefit of Postoperative Radiotherapy for Patients With Nonmetastatic Adrenocortical Carcinoma: A Population-Based Analysis. J Natl Compr Canc Netw 2021; 19:1425.</a></li><li><a class="nounderline abstract_t">Habra MA, Ejaz S, Feng L, et al. A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma. J Clin Endocrinol Metab 2013; 98:192.</a></li><li><a class="nounderline abstract_t">Gharzai LA, Green MD, Griffith KA, et al. Adjuvant Radiation Improves Recurrence-Free Survival and Overall Survival in Adrenocortical Carcinoma. J Clin Endocrinol Metab 2019; 104:3743.</a></li><li><a class="nounderline abstract_t">Fujii Y, Kageyama Y, Kawakami S, et al. Successful long-term disease-free survival following multimodal treatments in a patient with a repeatedly recurrent refractory adrenal cortical carcinoma. Int J Urol 2003; 10:445.</a></li><li><a class="nounderline abstract_t">Sperone P, Berruti A, Gorzegno G, et al. Long-term disease free survival in a patient with metastatic adreno-cortical carcinoma after complete pathological response to chemotherapy plus mitotane. J Endocrinol Invest 2006; 29:560.</a></li><li><a class="nounderline abstract_t">Schulick RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol 1999; 6:719.</a></li><li><a class="nounderline abstract_t">Bellantone R, Ferrante A, Boscherini M, et al. Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma. Surgery 1997; 122:1212.</a></li><li><a class="nounderline abstract_t">Meyer A, Niemann U, Behrend M. Experience with the surgical treatment of adrenal cortical carcinoma. Eur J Surg Oncol 2004; 30:444.</a></li><li><a class="nounderline abstract_t">Dy BM, Strajina V, Cayo AK, et al. Surgical resection of synchronously metastatic adrenocortical cancer. Ann Surg Oncol 2015; 22:146.</a></li><li><a class="nounderline abstract_t">Kemp CD, Ripley RT, Mathur A, et al. Pulmonary resection for metastatic adrenocortical carcinoma: the National Cancer Institute experience. Ann Thorac Surg 2011; 92:1195.</a></li><li><a class="nounderline abstract_t">Gaujoux S, Al-Ahmadie H, Allen PJ, et al. Resection of adrenocortical carcinoma liver metastasis: is it justified? Ann Surg Oncol 2012; 19:2643.</a></li><li><a class="nounderline abstract_t">Adam R, Chiche L, Aloia T, et al. Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. Ann Surg 2006; 244:524.</a></li><li><a class="nounderline abstract_t">Datrice NM, Langan RC, Ripley RT, et al. Operative management for recurrent and metastatic adrenocortical carcinoma. J Surg Oncol 2012; 105:709.</a></li><li><a class="nounderline abstract_t">Sabolch A, Feng M, Griffith K, et al. Adjuvant and definitive radiotherapy for adrenocortical carcinoma. Int J Radiat Oncol Biol Phys 2011; 80:1477.</a></li><li><a class="nounderline abstract_t">Magee BJ, Gattamaneni HR, Pearson D. Adrenal cortical carcinoma: survival after radiotherapy. Clin Radiol 1987; 38:587.</a></li><li><a class="nounderline abstract_t">Percarpio B, Knowlton AH. Radiation therapy of adrenal cortical carcinoma. Acta Radiol Ther Phys Biol 1976; 15:288.</a></li><li><a class="nounderline abstract_t">Wood BJ, Abraham J, Hvizda JL, et al. Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases. Cancer 2003; 97:554.</a></li><li><a class="nounderline abstract_t">Mayo-Smith WW, Dupuy DE. Adrenal neoplasms: CT-guided radiofrequency ablation--preliminary results. Radiology 2004; 231:225.</a></li><li><a class="nounderline abstract_t">Bauditz J, Quinkler M, Wermke W. Radiofrequency thermal ablation of hepatic metastases of adrenocortical cancer--a case report and review of the literature. Exp Clin Endocrinol Diabetes 2009; 117:316.</a></li><li><a class="nounderline abstract_t">Veltri A, Basile D, Calandri M, et al. Oligometastatic adrenocortical carcinoma: the role of image-guided thermal ablation. Eur Radiol 2020; 30:6958.</a></li><li><a class="nounderline abstract_t">Ilias I, Alevizaki M, Philippou G, et al. Sustained remission of metastatic adrenal carcinoma during long-term administration of low-dose mitotane. J Endocrinol Invest 2001; 24:532.</a></li><li><a class="nounderline abstract_t">Becker D, Schumacher OP. o,p'DDD therapy in invasive adrenocortical carcinoma. Ann Intern Med 1975; 82:677.</a></li><li><a class="nounderline abstract_t">El Ghorayeb N, Rondeau G, Latour M, et al. Rapid and Complete Remission of Metastatic Adrenocortical Carcinoma Persisting 10 Years After Treatment With Mitotane Monotherapy: Case Report and Review of the Literature. Medicine (Baltimore) 2016; 95:e3180.</a></li><li><a class="nounderline abstract_t">Lubitz JA, Freeman L, Okun R. Mitotane use in inoperable adrenal cortical carcinoma. JAMA 1973; 223:1109.</a></li><li><a class="nounderline abstract_t">Jensen JC, Pass HI, Sindelar WF, Norton JA. Recurrent or metastatic disease in select patients with adrenocortical carcinoma. Aggressive resection vs chemotherapy. Arch Surg 1991; 126:457.</a></li><li><a class="nounderline abstract_t">Hoffman DL, Mattox VR. Treatment of adrenocortical carcinoma with o,p'-DDD. Med Clin North Am 1972; 56:999.</a></li><li><a class="nounderline abstract_t">Tattersall MH, Lander H, Bain B, et al. Cis-platinum treatment of metastatic adrenal carcinoma. Med J Aust 1980; 1:419.</a></li><li><a class="nounderline abstract_t">Chun HG, Yagoda A, Kemeny N, Watson RC. Cisplatin for adrenal cortical carcinoma. Cancer Treat Rep 1983; 67:513.</a></li><li><a class="nounderline abstract_t">Haq MM, Legha SS, Samaan NA, et al. Cytotoxic chemotherapy in adrenal cortical carcinoma. Cancer Treat Rep 1980; 64:909.</a></li><li><a class="nounderline abstract_t">van Slooten H, van Oosterom AT. CAP (cyclophosphamide, doxorubicin, and cisplatin) regimen in adrenal cortical carcinoma. Cancer Treat Rep 1983; 67:377.</a></li><li><a class="nounderline abstract_t">Williamson SK, Lew D, Miller GJ, et al. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study. Cancer 2000; 88:1159.</a></li><li><a class="nounderline abstract_t">Khan TS, Sundin A, Juhlin C, et al. Vincristine, cisplatin, teniposide, and cyclophosphamide combination in the treatment of recurrent or metastatic adrenocortical cancer. Med Oncol 2004; 21:167.</a></li><li><a class="nounderline abstract_t">Johnson DH, Greco FA. Treatment of metastatic adrenal cortical carcinoma with cisplatin and etoposide (VP-16). Cancer 1986; 58:2198.</a></li><li><a class="nounderline abstract_t">Schlumberger M, Brugieres L, Gicquel C, et al. 5-Fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma. Cancer 1991; 67:2997.</a></li><li><a class="nounderline abstract_t">Urup T, Pawlak WZ, Petersen PM, et al. Treatment with docetaxel and cisplatin in advanced adrenocortical carcinoma, a phase II study. Br J Cancer 2013; 108:1994.</a></li><li><a class="nounderline abstract_t">Flynn SD, Murren JR, Kirby WM, et al. P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma. Surgery 1992; 112:981.</a></li><li><a class="nounderline abstract_t">Haak HR, van Seters AP, Moolenaar AJ, Fleuren GJ. Expression of P-glycoprotein in relation to clinical manifestation, treatment and prognosis of adrenocortical cancer. Eur J Cancer 1993; 29A:1036.</a></li><li><a class="nounderline abstract_t">Berruti A, Terzolo M, Sperone P, et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer 2005; 12:657.</a></li><li><a class="nounderline abstract_t">Fassnacht M, Terzolo M, Allolio B, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 2012; 366:2189.</a></li><li><a class="nounderline abstract_t">Abraham J, Bakke S, Rutt A, et al. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer 2002; 94:2333.</a></li><li><a class="nounderline abstract_t">Bonacci R, Gigliotti A, Baudin E, et al. Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma. Br J Cancer 1998; 78:546.</a></li><li><a class="nounderline abstract_t">Sperone P, Ferrero A, Daffara F, et al. Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr Relat Cancer 2010; 17:445.</a></li><li><a class="nounderline abstract_t">Redlich A, Boxberger N, Strugala D, et al. Systemic treatment of adrenocortical carcinoma in children: data from the German GPOH-MET 97 trial. Klin Padiatr 2012; 224:366.</a></li><li><a class="nounderline abstract_t">Raj N, Zheng Y, Kelly V, et al. PD-1 Blockade in Advanced Adrenocortical Carcinoma. J Clin Oncol 2020; 38:71.</a></li><li><a class="nounderline abstract_t">Habra MA, Stephen B, Campbell M, et al. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J Immunother Cancer 2019; 7:253.</a></li><li><a class="nounderline abstract_t">Geoerger B, Kang HJ, Yalon-Oren M, et al. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. Lancet Oncol 2020; 21:121.</a></li><li><a class="nounderline abstract_t">Barlaskar FM, Spalding AC, Heaton JH, et al. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. J Clin Endocrinol Metab 2009; 94:204.</a></li><li><a class="nounderline abstract_t">Haluska P, Worden F, Olmos D, et al. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol 2010; 65:765.</a></li><li><a class="nounderline abstract_t">Puzanov I, Lindsay CR, Goff L, et al. A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors. Clin Cancer Res 2015; 21:701.</a></li><li class="breakAll">Carden CP, Frentzas S, Langham M, et al. Preliminary activity in adrenocortical tumor (ACC) in phase I dose escalation study of intermittent oral dosing of OSI-906, a small-molecule insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor in patients with advanced solid tumors (abstract 3544). J Clin Oncol 2009; 27:15s. Abstract available online at http://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=65&amp;abstractID=31413 (Accessed on June 11, 2012).</li><li><a class="nounderline abstract_t">Lerario AM, Worden FP, Ramm CA, et al. The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial. Horm Cancer 2014; 5:232.</a></li><li><a class="nounderline abstract_t">Fassnacht M, Berruti A, Baudin E, et al. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol 2015; 16:426.</a></li><li class="breakAll">https://clinicaltrials.gov/ct2/show/NCT00778817?term=cixutumumab+and+adrenocortical+carcinoma&amp;rank=2 (Accessed on February 19, 2015).</li><li><a class="nounderline abstract_t">Naing A, Lorusso P, Fu S, et al. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. Br J Cancer 2013; 108:826.</a></li><li><a class="nounderline abstract_t">Chacón R, Tossen G, Loria FS, Chacón M. CASE 2. Response in a patient with metastatic adrenal cortical carcinoma with thalidomide. J Clin Oncol 2005; 23:1579.</a></li><li><a class="nounderline abstract_t">Boudou-Rouquette P, Alexandre J, Soubrane O, et al. Antitumoral effect of the bisphosphonate zoledronic acid against visceral metastases in an adrenocortical cancer patient. Ann Oncol 2009; 20:1747.</a></li><li><a class="nounderline abstract_t">Butler C, Butler WM, Rizvi AA. Sustained remission with the kinase inhibitor sorafenib in stage IV metastatic adrenocortical carcinoma. Endocr Pract 2010; 16:441.</a></li><li><a class="nounderline abstract_t">Lee JO, Lee KW, Kim CJ, et al. Metastatic adrenocortical carcinoma treated with sunitinib: a case report. Jpn J Clin Oncol 2009; 39:183.</a></li><li><a class="nounderline abstract_t">O'Sullivan C, Edgerly M, Velarde M, et al. The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer. J Clin Endocrinol Metab 2014; 99:1291.</a></li><li><a class="nounderline abstract_t">Kroiss M, Quinkler M, Johanssen S, et al. Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. J Clin Endocrinol Metab 2012; 97:3495.</a></li><li><a class="nounderline abstract_t">Wortmann S, Quinkler M, Ritter C, et al. Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. Eur J Endocrinol 2010; 162:349.</a></li><li><a class="nounderline abstract_t">Berruti A, Sperone P, Ferrero A, et al. Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. Eur J Endocrinol 2012; 166:451.</a></li><li><a class="nounderline abstract_t">Edgren M, Eriksson B, Wilander E, et al. Biological characteristics of adrenocortical carcinoma: a study of p53, IGF, EGF-r, Ki-67 and PCNA in 17 adrenocortical carcinomas. Anticancer Res 1997; 17:1303.</a></li><li><a class="nounderline abstract_t">Kamio T, Shigematsu K, Sou H, et al. Immunohistochemical expression of epidermal growth factor receptors in human adrenocortical carcinoma. Hum Pathol 1990; 21:277.</a></li><li><a class="nounderline abstract_t">Quinkler M, Hahner S, Wortmann S, et al. Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. J Clin Endocrinol Metab 2008; 93:2057.</a></li><li><a class="nounderline abstract_t">Hahner S, Kreissl MC, Fassnacht M, et al. [131I]iodometomidate for targeted radionuclide therapy of advanced adrenocortical carcinoma. J Clin Endocrinol Metab 2012; 97:914.</a></li><li><a class="nounderline abstract_t">Hahner S, Hartrampf PE, Mihatsch PW, et al. Targeting 11-Beta Hydroxylase With [131I]IMAZA: A Novel Approach for the Treatment of Advanced Adrenocortical Carcinoma. J Clin Endocrinol Metab 2022; 107:e1348.</a></li><li class="breakAll">HRA Pharma www.hra-pharma.com (Accessed on August 14, 2012).</li><li><a class="nounderline abstract_t">Castinetti F, Fassnacht M, Johanssen S, et al. Merits and pitfalls of mifepristone in Cushing's syndrome. Eur J Endocrinol 2009; 160:1003.</a></li><li><a class="nounderline abstract_t">Fassnacht M, Johanssen S, Quinkler M, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer 2009; 115:243.</a></li><li><a class="nounderline abstract_t">Paton BL, Novitsky YW, Zerey M, et al. Outcomes of adrenal cortical carcinoma in the United States. Surgery 2006; 140:914.</a></li><li><a class="nounderline abstract_t">Ribeiro RC, Pinto EM, Zambetti GP. Familial predisposition to adrenocortical tumors: clinical and biological features and management strategies. Best Pract Res Clin Endocrinol Metab 2010; 24:477.</a></li><li><a class="nounderline abstract_t">Wasserman JD, Novokmet A, Eichler-Jonsson C, et al. Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study. J Clin Oncol 2015; 33:602.</a></li><li><a class="nounderline abstract_t">Pinto EM, Chen X, Easton J, et al. Genomic landscape of paediatric adrenocortical tumours. Nat Commun 2015; 6:6302.</a></li><li><a class="nounderline abstract_t">Rodriguez-Galindo C, Krailo MD, Pinto EM, et al. Treatment of Pediatric Adrenocortical Carcinoma With Surgery, Retroperitoneal Lymph Node Dissection, and Chemotherapy: The Children's Oncology Group ARAR0332 Protocol. J Clin Oncol 2021; 39:2463.</a></li><li><a class="nounderline abstract_t">Raymond VM, Else T, Everett JN, et al. Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma. J Clin Endocrinol Metab 2013; 98:E119.</a></li><li><a class="nounderline abstract_t">Libè R, Groussin L, Tissier F, et al. Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity. Clin Cancer Res 2007; 13:844.</a></li><li><a class="nounderline abstract_t">Reincke M, Karl M, Travis WH, et al. p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. J Clin Endocrinol Metab 1994; 78:790.</a></li><li><a class="nounderline abstract_t">Sidhu S, Martin E, Gicquel C, et al. Mutation and methylation analysis of TP53 in adrenal carcinogenesis. Eur J Surg Oncol 2005; 31:549.</a></li><li><a class="nounderline abstract_t">Mendonca BB, Lucon AM, Menezes CA, et al. Clinical, hormonal and pathological findings in a comparative study of adrenocortical neoplasms in childhood and adulthood. J Urol 1995; 154:2004.</a></li><li><a class="nounderline abstract_t">Ribeiro RC, Pinto EM, Zambetti GP, Rodriguez-Galindo C. The International Pediatric Adrenocortical Tumor Registry initiative: contributions to clinical, biological, and treatment advances in pediatric adrenocortical tumors. Mol Cell Endocrinol 2012; 351:37.</a></li><li><a class="nounderline abstract_t">Lack EE, Mulvihill JJ, Travis WD, Kozakewich HP. Adrenal cortical neoplasms in the pediatric and adolescent age group. Clinicopathologic study of 30 cases with emphasis on epidemiological and prognostic factors. Pathol Annu 1992; 27 Pt 1:1.</a></li><li><a class="nounderline abstract_t">Dehner LP, Hill DA. Adrenal cortical neoplasms in children: why so many carcinomas and yet so many survivors? Pediatr Dev Pathol 2009; 12:284.</a></li><li><a class="nounderline abstract_t">McAteer JP, Huaco JA, Gow KW. Predictors of survival in pediatric adrenocortical carcinoma: a Surveillance, Epidemiology, and End Results (SEER) program study. J Pediatr Surg 2013; 48:1025.</a></li></ol></div><div id="topicVersionRevision">Topic 165 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30042120" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : European Society of Endocrinology Clinical Practice Guidelines on the Management of Adrenocortical Carcinoma in Adults, in collaboration with the European Network for the Study of Adrenal Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15008991" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Management of adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24081734" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Update in adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16172199" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Management of patients with adrenal cancer: recommendations of an international consensus conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8571201" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20026647" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10025460" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Pathologic features of prognostic significance for adrenocortical carcinoma after curative resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22143204" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27590329" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Lymphadenectomy for Adrenocortical Carcinoma: Is There a Therapeutic Benefit?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30443830" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Patterns of Lymph Node Recurrence in Adrenocortical Carcinoma: Possible Implications for Primary Surgical Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6272575" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Clinical and laboratory findings and results of therapy in 58 patients with adrenocortical tumors admitted to a single medical center (1951 to 1978).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11844815" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Adrenocortical carcinoma: clinical, morphologic, and molecular characterization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/474519" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Prognostic factors in adrenal cortical tumors. A mathematical analysis of clinical and morphologic data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7115060" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Treatment of adrenal carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16551738" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clinical review: Adrenocortical carcinoma: clinical update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16670169" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2325710" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13571886" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Cancer of the adrenal cortex; the natural history, prognosis and treatment in a study of fifty-five cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2253796" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Adrenocortical carcinoma. A retrospective study of a rare tumor with a poor prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3551152" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Diagnosis and treatment of functioning and nonfunctioning adrenocortical neoplasms including incidentalomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34850915" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Cytoreductive Surgery of the Primary Tumor in Metastatic Adrenocortical Carcinoma: Impact on Patients' Survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7379017" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A clinical and pathological study of adrenocortical carcinoma: therapeutic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10679640" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Adrenocortical carcinoma: clinical and laboratory observations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8176925" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Adrenal adenocarcinoma: a review of 53 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12478091" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Adrenocortical carcinoma: diagnosis, evaluation and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24615603" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Borderline resectable adrenal cortical carcinoma: a potential role for preoperative chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12045859" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Results of laparoscopic adrenalectomy for large and potentially malignant tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12146996" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Results of laparoscopic adrenalectomy for suspected and unsuspected malignant adrenal neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16847903" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Role of laparoscopy in the management of adrenal malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27390021" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20372905" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Laparoscopic resection is inappropriate in patients with known or suspected adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14718275" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Applicability of laparoscopic adrenalectomy in a prospective study in 150 consecutive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16360394" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Laparoscopic resection of adrenal cortical carcinoma: a cautionary note.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21831516" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Contemporary management of adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20580485" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18303532" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Laparoscopic radical adrenalectomy for cancer: long-term outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20137850" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25536088" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Laparoscopic versus Open Adrenalectomy for Stage I/II Adrenocortical Carcinoma: Meta-Analysis of Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22124842" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A debate on laparoscopic versus open adrenalectomy for adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24423978" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11572030" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14990639" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12612756" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Adrenocortical tumors: results of treatment and study of Weiss's score as a prognostic factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12826878" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Adrenal cortical neoplasms in the pediatric population: a clinicopathologic and immunophenotypic analysis of 83 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34850906" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Pathological and Genetic Stratification for Management of Adrenocortical Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20694732" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25456914" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A novel staging system for adrenocortical carcinoma better predicts survival in patients with stage I/II disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18973179" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2919718" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Pathologic features of prognostic significance in adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11571723" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Adrenocortical carcinoma. Clinical outcome at the end of the 20th century.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19912359" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20567001" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18187873" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17062775" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Prognostic parameters of metastatic adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25559399" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19139432" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19147773" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22048964" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Combined expression of BUB1B, DLGAP5, and PINK1 as predictors of poor outcome in adrenocortical tumors: validation in a Brazilian cohort of adult and pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24747642" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Integrated genomic characterization of adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25078331" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27165744" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22019901" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Differences in the molecular mechanisms of adrenocortical tumorigenesis between children and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23055545" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Low SGK1 expression in human adrenocortical tumors is associated with ACTH-independent glucocorticoid secretion and poor prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21088256" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : β-catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20959480" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12547710" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20660055" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22800756" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 andβ-catenin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30770352" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Targeted Assessment of G0S2 Methylation Identifies a Rapidly Recurrent, Routinely Fatal Molecular Subtype of Adrenocortical Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17395972" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Adrenocortical cancer: pathophysiology and clinical management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20738315" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : What is the best approach to an apparently nonmetastatic adrenocortical carcinoma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : First randomized trial on adjuvant mitotane in adrenocortical carcinoma patients: The Adjuvo study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20668036" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1455321" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : An eleven-year experience with adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17554118" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Adjuvant mitotane treatment for adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21386792" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Adrenocortical carcinoma: a clinician's update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21386792" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Adrenocortical carcinoma: a clinician's update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21383612" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : The argument for mitotic rate-based grading for the prognostication of adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34400803" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Adjuvant platinum-based chemotherapy in radically resected adrenocortical carcinoma: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12652623" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Adrenocortical carcinoma in children: a role for etoposide and cisplatin adjuvant therapy? Preliminary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11106117" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6648806" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Adrenal cortical carcinoma--a continuing challenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5923598" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Adrenal cortical carcinoma. Clinical features of 138 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6861107" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Adrenal cortical carcinoma. A study of 77 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9597936" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Adrenocortical carcinoma: surgery and mitotane for treatment and steroid profiles for follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11260859" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Clinical management of malignant adrenal tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11343545" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Adrenocortical carcinoma: surgical progress or status quo?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7736405" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Adrenocortical carcinoma. A clinical study and treatment results of 52 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9745410" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11004719" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Clinical results of the use of mitotane for adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17554125" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Adjuvant mitotane therapy of adrenal cancer - use and controversy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8490842" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11745214" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2913342" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : The Cleveland Clinic experience with adrenal cortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9394846" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Adrenocortical carcinoma: experience in 45 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8180029" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10199802" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Comment--Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28324035" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24302750" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30991359" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6537915" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : The treatment of adrenocortical carcinoma with o,p'-DDD: prognostic implications of serum level monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22048971" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18824557" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21470991" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16471038" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Clinical role of determination of plasma mitotane and its metabolites levels in patients with adrenal cancer: results of a long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23704714" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10852456" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25144458" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : CYP2W1 is highly expressed in adrenal glands and is positively associated with the response to mitotane in adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23524664" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25201518" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Short-term variation in plasma mitotane levels confirms the importance of trough level monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16621901" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16368753" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22076881" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : FDG PET in the management of patients with adrenal masses and adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24990404" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Impact of¹⁸F-FDG PET/CT on the management of adrenocortical carcinoma: analysis of 106 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1903011" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Mitotane increases the blood levels of hormone-binding proteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21917861" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12364417" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Long-term (15 years) outcome in an infant with metastatic adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37435450" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Characterization of hyperlipidemia secondary to mitotane in adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2830062" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : The effect of o,p'-DDD on adrenal steroid replacement therapy requirements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23162091" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24627099" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Hair cortisol measurement in mitotane-treated adrenocortical cancer patients</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32164326" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Recovery of Adrenal Insufficiency Is Frequent After Adjuvant Mitotane Therapy in Patients with Adrenocortical Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25411236" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Ovarian macrocysts and gonadotrope-ovarian axis disruption in premenopausal women receiving mitotane for adrenocortical carcinoma or Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21883349" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21220434" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Mitotane has a strong and a durable inducing effect on CYP3A4 activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19402169" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Radiotherapy in adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16895957" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1709336" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Radiation therapy for adjunctive treatment of adrenal cortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25754631" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Adjuvant radiation therapy improves local control after surgical resection in patients with localized adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29748889" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Adjuvant Radiation is Associated with Improved Survival for Select Patients with Non-metastatic Adrenocortical Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30900615" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Adjuvant radiotherapy after surgical resection for adrenocortical carcinoma: A systematic review of observational studies and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34902831" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Benefit of Postoperative Radiotherapy for Patients With Nonmetastatic Adrenocortical Carcinoma: A Population-Based Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23150683" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31220287" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Adjuvant Radiation Improves Recurrence-Free Survival and Overall Survival in Adrenocortical Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12887367" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Successful long-term disease-free survival following multimodal treatments in a patient with a repeatedly recurrent refractory adrenal cortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16840836" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Long-term disease free survival in a patient with metastatic adreno-cortical carcinoma after complete pathological response to chemotherapy plus mitotane.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10622498" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9426440" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15063900" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Experience with the surgical treatment of adrenal cortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25092161" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Surgical resection of synchronously metastatic adrenocortical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21958764" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Pulmonary resection for metastatic adrenocortical carcinoma: the National Cancer Institute experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22526905" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Resection of adrenocortical carcinoma liver metastasis: is it justified?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16998361" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22189845" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Operative management for recurrent and metastatic adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20675074" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Adjuvant and definitive radiotherapy for adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3121234" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Adrenal cortical carcinoma: survival after radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/62490" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Radiation therapy of adrenal cortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12548596" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14990812" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Adrenal neoplasms: CT-guided radiofrequency ablation--preliminary results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19053031" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Radiofrequency thermal ablation of hepatic metastases of adrenocortical cancer--a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32621242" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Oligometastatic adrenocortical carcinoma: the role of image-guided thermal ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11508789" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Sustained remission of metastatic adrenal carcinoma during long-term administration of low-dose mitotane.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1137262" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : o,p'DDD therapy in invasive adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27043680" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Rapid and Complete Remission of Metastatic Adrenocortical Carcinoma Persisting 10 Years After Treatment With Mitotane Monotherapy: Case Report and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4739370" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Mitotane use in inoperable adrenal cortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1706914" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Recurrent or metastatic disease in select patients with adrenocortical carcinoma. Aggressive resection vs chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5034421" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Treatment of adrenocortical carcinoma with o,p'-DDD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7190216" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Cis-platinum treatment of metastatic adrenal carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6682704" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Cisplatin for adrenal cortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7448828" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Cytotoxic chemotherapy in adrenal cortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6687835" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : CAP (cyclophosphamide, doxorubicin, and cisplatin) regimen in adrenal cortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10699907" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15299189" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Vincristine, cisplatin, teniposide, and cyclophosphamide combination in the treatment of recurrent or metastatic adrenocortical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3756767" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Treatment of metastatic adrenal cortical carcinoma with cisplatin and etoposide (VP-16).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2044046" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : 5-Fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23652308" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Treatment with docetaxel and cisplatin in advanced adrenocortical carcinoma, a phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1360713" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8098948" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Expression of P-glycoprotein in relation to clinical manifestation, treatment and prognosis of adrenocortical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16172198" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22551107" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Combination chemotherapy in advanced adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12015757" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9716042" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20410174" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23143764" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Systemic treatment of adrenocortical carcinoma in children: data from the German GPOH-MET 97 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31644329" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : PD-1 Blockade in Advanced Adrenocortical Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31533818" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31812554" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18854392" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19649631" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25212606" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25212606" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24849545" id="rid181" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>182 : The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25795408" id="rid182" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>183 : Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25795408" id="rid183" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>184 : Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23412108" id="rid184" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>185 : Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15735134" id="rid185" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>186 : CASE 2. Response in a patient with metastatic adrenal cortical carcinoma with thalidomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19633056" id="rid186" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>187 : Antitumoral effect of the bisphosphonate zoledronic acid against visceral metastases in an adrenocortical cancer patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20061282" id="rid187" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>188 : Sustained remission with the kinase inhibitor sorafenib in stage IV metastatic adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19168875" id="rid188" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>189 : Metastatic adrenocortical carcinoma treated with sunitinib: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24423320" id="rid189" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>190 : The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22837187" id="rid190" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>191 : Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19903796" id="rid191" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>192 : Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22189997" id="rid192" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>193 : Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9137490" id="rid193" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>194 : Biological characteristics of adrenocortical carcinoma: a study of p53, IGF, EGF-r, Ki-67 and PCNA in 17 adrenocortical carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2312105" id="rid194" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>195 : Immunohistochemical expression of epidermal growth factor receptors in human adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18334586" id="rid195" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>196 : Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22170726" id="rid196" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>197 : [131I]iodometomidate for targeted radionuclide therapy of advanced adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34904171" id="rid197" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>198 : Targeting 11-Beta Hydroxylase With [131I]IMAZA: A Novel Approach for the Treatment of Advanced Adrenocortical Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34904171" id="rid198" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>199 : Targeting 11-Beta Hydroxylase With [131I]IMAZA: A Novel Approach for the Treatment of Advanced Adrenocortical Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19289534" id="rid199" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>200 : Merits and pitfalls of mifepristone in Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19025987" id="rid200" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>201 : Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17188138" id="rid201" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>202 : Outcomes of adrenal cortical carcinoma in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20833338" id="rid202" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>203 : Familial predisposition to adrenocortical tumors: clinical and biological features and management strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25584008" id="rid203" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>204 : Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25743702" id="rid204" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>205 : Genomic landscape of paediatric adrenocortical tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33822640" id="rid205" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>206 : Treatment of Pediatric Adrenocortical Carcinoma With Surgery, Retroperitoneal Lymph Node Dissection, and Chemotherapy: The Children's Oncology Group ARAR0332 Protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23175693" id="rid206" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>207 : Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17289876" id="rid207" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>208 : Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8126158" id="rid208" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>209 : p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15922892" id="rid209" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>210 : Mutation and methylation analysis of TP53 in adrenal carcinogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7500445" id="rid210" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>211 : Clinical, hormonal and pathological findings in a comparative study of adrenocortical neoplasms in childhood and adulthood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22040600" id="rid211" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>212 : The International Pediatric Adrenocortical Tumor Registry initiative: contributions to clinical, biological, and treatment advances in pediatric adrenocortical tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1736241" id="rid212" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>213 : Adrenal cortical neoplasms in the pediatric and adolescent age group. Clinicopathologic study of 30 cases with emphasis on epidemiological and prognostic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19326954" id="rid213" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>214 : Adrenal cortical neoplasms in children: why so many carcinomas and yet so many survivors?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23701777" id="rid214" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>215 : Predictors of survival in pediatric adrenocortical carcinoma: a Surveillance, Epidemiology, and End Results (SEER) program study.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
